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Besides Bone Mineral Density (BMD), viscoelastic properties like viscosity (η), elastic 
modulus (E) and loss tangent (tan δ) of bone are also crucial determinants of bone 
strength. However, these properties were seldom assessed in the prevalent drug or whole-
body vibration (WBV) therapy. The first phase of this thesis was to examine whether 
there is a beneficial effect of PTH and ibandronate combined treatment in the 
ovariectomized (OVX) rat bone. Traditional BMD measurement together with serum 
biomarker test, micro-computed tomography (μCT) and a specially designed mechanical 
test were adopted. Maximum load, strength–strain indices (SSIy) and bone formation 
marker of the combination group were significantly higher than both monotherapy groups 
in tibia metaphysis. Compared to the previous studies which showed impedance from 
bisphosphonates in combination therapy, our phase 1 results revealed that ibandronate 
does not block the anabolic effects of PTH. 
Viscoelastic response of ovariectomy and treatment was further examined using 
nanoindentation and dynamic mechanical analyzer (DMA) test. Firstly, in the 
nanoindentation test conducted on distal femoral metaphysis, ovariectomy induced 
deterioration in η and E was observed. Different drugs had selective effects on bone 
especially in preserving geometry, E and η. The concurrent administration of PTH and 
ibandronate was shown to offer an added advantage in maintaining BMD and cortical 
bone area by an increased periosteal formation and a decreased endocortical resorption. η 
was prominently restored in combined treatment group. It is in accordance with an 
observed denser alignment of collagen fibers and hydroxyapatite crystals matrix with 
fewer pores, which may play an important role in hindering fracture propagation. 
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Secondly, DMA test on cortical samples from control and drug treated femoral diaphysis 
were conducted. The BMD of femoral diaphysis cortical bone samples did not show any 
difference between groups, whereas combination treatment was demonstrated to have a 
better therapeutic effect in terms of a higher ultimate force in bending test, increased E’ 
(storage modulus) and tan δ. This indicates that these viscoelastic changes accompanying 
ovariectomy and treatment would be ignored in clinical screening by an unchanged BMD 
value. It is the first time that positive correlations between tan δ and ultimate strength of 
the bone were observed during normal daily activity frequency range (0.9-6 Hz). 
Finally, BMD, mechanical and viscoelastic properties of WBV treated OVX rat were 
investigated. There is no substantial effects resulting from 16 weeks of low-magnitude, 
high-frequency vibration treatment (30 Hz, 0.3 g) on tibia BMD and viscoelasticity were 
found. In fact, the WBV treated rats have significantly lower lumbar BMD than non-
treated group. Maximum load from rat vertebrae compression test was significantly 
reduced in WBV treated rats. This result indicates that the prevalent vibration therapy 
may not provide a curative effect in all conditions. Since the optimal parameters were 
still under research, WBV should not be recommended for long-term usage. Taken 
together, the results of the present work provide a better understanding of pathogenesis of 
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1.1 Osteoporosis and skeletal fragility 
Bone is a complex, hierarchically organized organ system whose composition and 
structure are closely related to, and in many ways controlled by, the functional demands 
made upon it (Morgan et al., 2008). Besides providing mechanical strength and 
protection to inner soft organs, bone is also the primary site for hematopoiesis and 
mineral storage. Osteoporosis is a worldwide public health problem. It is a disease 
characterized by low bone mass and structural deterioration of bone tissue, leading to 
bone fragility and an increased susceptibility to fractures. Normal bone turnover involves 
a balance between the process of bone resorption and bone formation in which osteoclast 
resorb bone and osteoblasts secrete new organic matrix into the resorption cavity 
(Manolagas et al., 2000). In postmenopausal women, the rate of bone turnover increases 
dramatically and can remain elevated for up to 40 years, leading to continuous, 
progressive bone loss (Garnero et al., 1996). The basis for the increased bone turnover is 
thought to be due in part to a shortening of lifespan of osteoblasts and a prolongation of 
the lifespan of osteoclasts (Manolagas et al., 2000). Several interacting factors, such as 
clinical, medical, behavioral, nutritional and genetic variables, contribute together to the 
risk of osteoporotic fracture (Cooper et al., 1992). Fractures induced by osteoporosis 
cause a great burden to society due to increased mortality and disability and the resultant 
expenses of caring. In 1990, there were 1.7 million hip fractures alone worldwide; with 
changes in population demographics, this figure is expected to rise to 6 million by 2050, 
as reported by World Health Organization (Kanis et al., 1994).  
The pathogenesis of osteoporosis is mainly due to the depletion of estrogen caused by 
post-menopause or ageing effects. The most prevalent clinical tool for osteoporotic 
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fracture prediction and treatment efficacy assessment is the bone mineral density (BMD) 
measurement by dual-energy x-ray absorptiometry (DXA) or quantitative computed 
tomography (QCT). While DXA measures areal bone density (g/cm
2
), QCT determines 
volumetric density (g/cm
3
). Previous large prospective studies have shown that a 
reduction in BMD causes increase in fracture risk (Hui et al., 1988). In the subsequent 
studies, BMD at various skeletal sites were assessed. Among different sites, femoral neck 
BMD is shown to be the most representative predictor for osteoporotic fracture (Melton 
et al., 1993, Cummings et al., 1994, Marshall et al., 1996). However, after years of 
clinical studies, some researchers believe that BMD measurement alone does not provide 
sufficient evaluation of the trabecular architecture (Hildebrand et al., 1999), actual 
stiffness or the ability to withstand an applied force on bones (Stürmer et al., 2006). 
Furthermore, it is becoming generally accepted that high BMD does not always relate to 
low fracture risk in elders (Wilkin and Devendra, 2001, Cefalu, 2004, Kumasaka et al., 
2005) and drug-treated patients (Watt et al., 2000).  
Besides BMD, numerous other critical determinants of bone quality have been 
investigated with the development of techniques, for instance, the bone structural analysis. 
The current generation of DXA and QCT is now able to perform hip structural analysis 
which is widely used together with BMD in clinical prediction of osteoporotic fracture. 
Another invasive technique, micro-computed tomography (μCT), has provided an 
opportunity to define three-dimensional microstructural aspects of bone and in 
conjunction with newer methods of measuring bone strength (Turner et al., 2000). 
However, due to the high dose exposure of radiation to acquire micro-level structure, 
μCT is mainly used in research purpose. In addition, several serum and urine biochemical 
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markers are available which provide an index of the overall rate of bone remodeling/ time 
point. These biomarkers are collagen degradation products from remodeling process, i.e., 
C-terminal cross-linked telopeptide of type I collagen (CTX) and N-terminal pro-peptide 
of type I collagen (P1NP). Although biomarker is a useful non-invasive tool to study the 
dynamic bone remodeling for both experimental and research purpose, the validity of this 
measurement is subject to the dietary and nutritional changes in individual. Recently, 
bone viscoelasticity, a new determinant which correlates with material load-bearing 
capacity, has raised a growing concern (Ammann et al., 2007, Brennan et al., 2009). The 
viscoelasticity of bone arises from the void collapse, densification of cancellous bone and 
natural viscoelastic response of collagen as a polymer. Certain viscoelastic properties of 
compact bone (i.e. loss tangent) have been demonstrated as an effective tool to test 
human bone (Yamashita et al., 2001). Furthermore, Les (2005) reported that long-term 
ovariectomy (induced osteoporosis) decreases ovine compact bone viscoelasticity. These 
previous studies showed deterioration in viscoelasticity of bone may possibly associate 
with the development of osteoporosis. However, there is still a lack of characterization of 
various treatment effects on osteoporotic bone viscoelasticity. For a better understanding 
of pathogenesis and drug efficacy in osteoporosis, timely investigations into bone 
viscoelasticity is necessary. This chapter will provide a brief overview of the 
determinants of bone strength in general, and more attention will be given to emerging 
techniques for viscoelasticity measurement and applications.  
1.2 Literature review of bone strength determinants 
Strength of bone is dependent on two main individual physical/structural factors: quantity 
and quality (Chesnut et al., 2001). Bone quantity consists of density and size, which 
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together form bone mass. Bone quality consists of structural and material properties. In 
this chapter, two distinctive surrogates of quantity and quality -- BMD and viscoelasticity, 
will be reviewed and discussed respectively. 
1.2.1 Bone mineral density and fracture prediction 
BMD measurement by dual energy X-ray absorptiometry (DXA) is widely used to 
diagnose osteoporosis and evaluate treatment effect (Kanis et al., 1997). The World 
Health Organization (WHO) in 1994 defines osteoporosis as a BMD value that is 2.5 
standard deviations (SDs) or more below the mean of a young adult of the same sex as 
the subject (T-score) (Kanis, 1994). The question of how well does measurement of 
BMD predict occurrence of osteoporotic fracture has been under debate for decades. 
Early precursors in the field proposed a rule that the lower the BMD, the greater the 
fracture risk (Kanis, 1994, Marshall et al., 1996). This finding was based on a meta-
analysis of existing clinical data of non-treated patients. This substantial work was further 
extended by two research groups, in which the data from antiresorptive drug treated 
patients were taken into account. According to Wasnich and Miller, risk reduction was 
estimated to be 54% for an 8% BMD increase (Wasnich and Miller, 2000). A more recent 
study reported a risk reduction of 3% for a 1% BMD increase (Cummings et al., 2002). 
Thus, the earlier study determined that changes in BMD appeared to explain most of the 
observed risk reduction, whereas the more recent study determined that it explained only 
a fraction of the observed risk reduction. This discrepancy may partially reveal the non-
linear and non-proportional relationship between BMD increase and fracture risk 
reduction.  There seems to be (1) a markedly reduced fracture risk even with small 
increase in BMD; (2) a fracture risk reduction that may occur immediately (i.e. within the 
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1st year of treatment) and not increase despite subsequent BMD build; and (3) no dosage-
related fracture risk reduction despite dosage-related increases in BMD. These meta-
analyses suggest that other factors may partially account for the some of the variability 
between increase in BMD and the observed risk reduction with treatments. 
In order to explain the loose correlation of fracture risk and BMD increase, Michelotti 
and Clark‟s research group has successfully characterized the femoral neck length and 
hip fracture risk (Michelotti and Clark, 1999). Their results have recognized the increased 
fracture risk associated with decreased BMD, and more importantly, associated with both 
smaller bone diameter and decreased cortical thickness. More recently, a research group 
has established the use of biochemical markers and paved the way for measuring bone 
turnover in osteoporosis (Delmas et al., 2000). Furthermore, recent studies of drug 
therapies for osteoporosis have focused on the relationship between bone turnover and 
fracture risk prediction. These promising studies suggest that besides BMD, there are 
other unexplored surrogates of bone strength prediction, especially in the field of bone 
quality.  Viscoelasticity, which will be discussed in the next subsection, is one of them. 
1.2.2 Viscoelasticity of bone 
As a biological material, the bone exhibits a complex hierarchical structure with micro-
components dynamically undergoing remodeling, which results in complicated 
mechanical properties (Akkus et al., 2004). The viscoelasticity of bone arises from the 
void collapse, densification of cancellous bone and the natural viscoelastic response of 
collagen as a polymer (Garner et al., 2000). Collagen fibrils are strengthened by mineral 
deposits, and vice versa. It is not yet clear whether viscoelastic parameters are a dominant 
player in prediction of fracture risk. However, viscoelastic properties are known to be 
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significant predictors of the impact strength of polymers which share similarities with 
bone collagen (Nielsen and Landel, 1994). The viscoelastic properties of bone have been 
shown to correlate with the ultimate strength and toughness of the tissue (Yeni et al., 
2004). If changes in the viscoelastic properties of bone material accompany osteoporosis, 
then fracture risk could be increase dramatically without altering BMD.  
Currently, there are two common experimental methods to determine bone viscoelasticity. 
The first method, which is traditionally used in large animal models, is a determination of 
bone tangent delta (tan δ), storage modulus (E’) and loss modulus (E’’) by Dynamic 
Mechanical Analyzer (DMA). During the experimental process, a sinusoidal stress is 
applied and the strain in the material is measured. Frequency of the applied stress and 
temperature is usually varied. Smith and Keiper, had, for the first time, measured the 
dynamic mechanical properties of bone and reported a frequency-dependent property 
(Smith and Keiper, 1965). Later on, Lakes et al. described the viscoelastic response of 
bone under tensional loading as function of temperature (Lakes and Katz, 1979). These 
novel studies suggest that the viscoelastic behavior of bone may have a pronounced effect 
on its fracture behavior under dynamic loading. Since different parameters and conditions 
were adopted in early investigations, fair comparisons of the results between different 
research groups seemed problematic. Thus, a standardization of the use of DMA to assess 
the viscoelasticity of bone is conducted by Yamashita in 2001. Effects of stress levels, 
temperature, size etc. were tested in this study. Les et al. (2004) have successfully 
extended the previous work to further characterize effects of architecture, mineralization 
and remodeling of the bone on viscoelastic properties of bone.  In 2005, Les and his 
research group applied their findings to osteoporotic bone and observed that long-term 
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ovariectomy decreases ovine compact bone viscoelasticity. Furthermore, chronic kidney 
disease was recently found to decrease compact bone tanδ without alteration in BMD 
(Iwasaki et al. 2011). Despite the encouraging results from large animal models (i.e. 
bovine, ovine), viscoelasticity of small animals (i.e. rodents) is not yet unveiled, partially 
due to the size limits. Studying viscoelasticity in small animal offers an advantage of 
faster experimental outcome due to the shorter life cycle, and less ethical issue involved. 
A newer method, which has gained more attention nowadays, is to investigate viscosity 
(η), elastic modulus (E) and hardness (H) by Nanoindentation. This method has been 
applied in recent years to measure E and contact hardness H of bone matrix at high 
resolution of load and displacement (Oliver and Pharr, 1992). Brennan et al. (2009) has 
reported selective modifications of E and H by different treatment in osteoporotic rat 
model. In one recent study, the precursory Voigt model was successfully used to describe 
the creep behavior of bone matrix during the holding period of indentation (Kim et al., 
2010). Viscosity η of young and old bone was calculated during creep behavior. The 
results indicated that prolonged creep deformation (lower η) can play an important role in 
the long-term degradation of mechanical stability of osteoporotic bone. However, η of 
osteoporotic bone, in comparison with healthy/treated bone, has not been rigorously 
investigated in previous studies. 
As discussed above, DMA and Nanoindentation have their merits and flaws. While DMA 
is prevalently used to characterize whole bone tan δ in macro size specimens, 
Nanoindentation is employed in mapping hierarchical nano-scale viscosity and elasticity. 
Nevertheless, the ultimate objective of these two different techniques is to further 
develop their potential application in the field of osteoporosis and its treatment. 
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1.3 Objectives and hypotheses  
As reviewed in section 1.2, bone viscoelasticity has revealed its potential correlation with 
fracture. Comparing to conventional bone strength predictor BMD, however, the 
application of bone viscoelasticity is yet to be thoroughly studied.  
Research gaps for the current study of bone viscoelasticity and the response of different 
osteoporotic therapies are summarized below:  
 Anabolic and antiresorptive mono treatments have been proven effective in 
treatment of osteoporosis. However, whether the concurrent use of these two 
different treatments would produce an additive effect by reducing fracture risk is 
still controversial. In addition, none have used viscoelastic parameters to 
investigate the existence of additive effect in concurrent treatment.   
 The detailed mechanism of Whole Body Vibration (WBV) therapy, as a newly 
emerged non-pharmaceutical mean to treat osteoporosis, has yet to be explored 
and understood. None have used viscoelastic parameters to investigate the 
existence of beneficial effect from WBV therapy. 
 It is not yet clear whether bone viscoelasticity plays an important role in the 
prediction of osteoporotic fracture risk, as compared to BMDs. 
The main aim of this study is to explore the drug treatment and vibration therapy induced 
changes occurred in osteoporotic bone strength. Bone strength here, is characterized by 
both conventional quantity parameters – BMDs, ultimate load, etc., and also by material 
quality means – bone viscoelasticity, μCT indices etc.  
The specific objectives of this study are to: 
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 Study the density and microarchitectural changes in ovariectomized (OVX, an 
established method to induce osteoporosis which will be discussed in Chapter 2) 
rat bone given treatment of parathyroid hormone (anabolic), bisphosphonate 
(antiresorptive) and combination treatment using BMD and μCT measurements. 
 Investigate viscoelastic properties differences (viscosity η and tanδ) in OVX rat 
bone between vehicle and drug treated groups using nanoindentation and DMA. 
 Investigate viscoelastic properties differences (tanδ) in OVX rat bone between 
vehicle and WBV induced mechanical stimulation groups using DMA. 
 Examine the correlations between bone viscoelasticity and traditional bone 
quality parameters (BMD, ultimate strength, stress, stiffness). 
The hypotheses are: 
 The combination treatment offers an advantage over mono therapy. 
 Nano-viscoelasticity (viscosity η) of osteoporotic bone can be influenced by 
treatment. 
 Macro-viscoelasticity (tanδ) of osteoporotic bone can be influenced by treatment. 
And it is correlated with ultimate strength of the bone.  
 The long-term use of WBV can alleviate the bone loss due to osteoporosis, in 
terms of bone mineral density and bone strength.  
 The rat skeleton which received WBV therapy will response and damp oscillatory 
stress more efficiently. 
The results of the present study may provide a better understanding of pathogenesis of 
osteoporosis, and will present a novel evaluation of different osteoporotic medication 
efficacy in bone viscoelasticity aspect. It is understood that there is a difference between 
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rodent and human bone inherent structure. However, due to ethical issues, tests on larger 
animal models are not within the scope of this study. 
1.4 Overall design 
According to the two different types of anti-osteoporotic therapies which will be 
investigated – medical treatments and whole body vibration, the proposed measurements 
are divided into the following two phases. 
Phase 1: medical treatments (Chapter 3, 4, 5) 
 
Ninety female Sprague Dawley rats (Laboratory Animal Centre, National University of 
Singapore) aged 10 to 12 weeks were housed at 25ºС under a 12:12-hour light-dark cycle 
and fed with a standard rodent diet (Harland, Model T.2018S) and water ad libitum. The 
animals were subjected to OVX or sham surgery one week after acclimatization at the 
animal holding unit. The rats were divided into the following 5 groups: (1) Vehicle-
treated sham operated group (SHM); (2) Vehicle-treated ovariectomized group (OVX); (3) 
hPTH (1-34) treated ovariectomized group (PTH); (4) ibandronate-treated 
ovariectomized group (IBN) and (5) combined hPTH (1-34) and ibandronate treated 
ovariectomized group (COM). Human parathyroid hormone (hPTH (1–34), Sigma-
Aldrich, Singapore) and ibandronic acid (Roche Diagnostics GmbH, Mannheim, 
Germany) were diluted in 0.9% saline. Starting from week 4 post-surgery, 10 μg/kg body 
weight of hPTH (1-34) (Gittens et al., 2004) and/or 7 μg/kg body weight ibandronate 
(Bauss et al., 2002) or its vehicle (0.9% saline) was administered subcutaneously once a 
week until week 12 to the respective groups. All animal experiments were conducted in 
accordance with the approved protocol from the Institutional Animal Care and Use 
Committee (IACUC) at National University of Singapore.  
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For destructive studies (i.e., mechanical tests), every two weeks several animals from 
each group were euthanized by carbon-dioxide asphyxiation as indicated by arrow in 
Fig.1.1.  
Fig.1.1. Overall design of phase 1. 
 
After sacrifice of the animals, four bones (right and left tibia, femur) were harvested and 
distributed for different purposes (Fig. 1.2): Proximal tibia bone and rat serum will be 
used in Chapter 3 to establish the OVX model with drug treatments; Distal femur bone 
will be consumed in Chapter 4 to characterize the nano-level viscoelastic change; 
Diaphyseal femur bone will be adopted Chapter 5 to characterize the macro-level 





Fig.1.2. Bone usage in phase 1. 
 
Phase 2: whole body vibration therapy (Chapter 6) 
Twelve ex-breeder female Sprague-Dawley (SD) rats of the age 6-8 weeks were 
subjected to OVX or SHM surgery. The rats were divided into the following 3 groups: (1) 
sham surgery operated rats group (SHM); (2) ovariectomized rats group without WBV 
treatment (OVX); (3) WBV treated ovariectomized rats group (VIB), with n=4/group. 
Starting from 4th week post-surgery, 0.3g, 30 Hz WBV was administered to VIB group, 
20 min/day for 16 weeks (Fig. 1.3). At weeks 20, animals were euthanized by carbon-




Fig.1.3. Overall design of phase 2. 
 
Femur, tibia and lumbar vertebral bones were harvested and distributed for different 
purposes (Fig. 1.4): Proximal tibia and spine bone will be used to establish the OVX 
model with WBV therapy and diaphyseal femur bone is planned to be used to 
characterize the macro-level viscoelastic change.  
 





t-test analysis was performed by Dr. Chan Yiong Huak (Head of the Biostatistics) to 
calculate sample size of the study, based on preliminary data of 12 weeks mean BMD of 
OVX (613 ± 28 mg/cm
3
) and SHM (780 ± 11 mg/cm
3
) groups. The result manifested that 
a minimal of two animals per each group was enough to give statistical power. Also, we 
have adopted mixed-model and Bonferroni test. The analysis has taken into account that 
two bones are from same rat sample, using rat as the random factor.  
Table 1.1. t-test sample size calculator shows at least 2 rats were needed to achieve 80% 
and 90% statistical power. 
 
Thus, the phase 1 study was conducted with two rats per SHM and OVX group, three rats 
per treatment group in the beginning. However, in the process of experiment we do notice 
the limitation that the sample size was calculated from preliminary pQCT data, which 
may not be compliant with other testing methods, i.e., mechanical test. Therefore, later on 
more rats were added into several critical time-points (week 0, 4, 8, 12) to further confirm 






2 Sample T   
mean diff =  167 
sd diff =  28 
alpha 5%   
sample size 2-sided 
80% power 1.44135 

























2.1 Medical treatments 
The patients who have osteoporosis by bone mineral density criteria, with a T-score of -
2.5 or below, should begin medical treatment. After years of clinical studies in the 
treatment of osteoporosis, two distinct classes of drugs, namely the antiresorptive and 
anabolic agents, proved to be effective and are now available on the market. 
Antiresorptive medications like estrogens, selective estrogen receptor modulator 
(raloxifene), bisphosphonates (alendronate, risedronate, and ibandronate) and calcitonins, 
work by reducing rates of bone resorption. Anabolic agent, teriparatide (parathyroid 
hormone), works by accelerating bone remodeling which includes both bone resorption 
and formation. 
The currently approved medications include alendronate (Fosamax), risedronate 
(Actonel), and raloxifene (Evista) for prevention and treatment of osteoporosis; 
Teriparatide (Forteo) and nasal calcitonins spray (Miacalcin) for treatment only; and 












2.1.1 Antiresorptive agents 




Medication FDA status 
Bisphosphonates  
Fosamax (Alendronate) Approved for prevention and treatment 
Actonel (Risedronate) Approved for prevention and treatment 
Bonviva (Ibandronate) Approved for daily use  
Zometa (Zolendronate) In phase 3 trials 
Calcitonins  
Nasal spray Treatment of osteoporosis 
Oral calcitonin In phase 3 trials 
Estrogens/hormones  
Premarin (conjugated estrogen) Prevention if other medications 
contraindicated or not tolerated Prempro (conjugated strogen MPA) 
SERMS  
Evista (Raloxifene) Approved for prevention and treatment 
Lasofoxifene In phase 3 trials 
Basodoxifene In phase 3 trials 
Arzoxifene In phase 3 trials 
Anabolic medications 
Forteo (teriparatide) Treatment of osteoporosis 
Preos (PTH [1-84]) In phase 3 trials 
 
As shown in Table 2.1, there are mainly five groups of antiresorptive medications: 
Estrogen/SERM: the estrogen depletion is the main source of osteoporosis which causes 
the increased survival rate of osteoclast and an elevated resorption. A direct refill of the 
depleted hormone was thus being considered. Estrogens are proven to be extremely 
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effective at reducing bone turnover and preserving or increasing bone mass in healthy 
postmenopausal women and those with osteoporosis. Women receiving estrogen had a 50% 
reduced vertebral fracture occurrence compared with those receiving placebo (Lindsay et 
al., 1980). However, data from Women‟s Health Initiative showing an increased risk of 
breast cancer and cardiovascular disease have dramatically dampened enthusiasm for the 
long-term use of estrogen (Rossouw et al., 2002). Therefore, ultra-low-dose estrogens are 
being explored and appear to have effects on bone turnover and bone mass consistent 
with active Antiresorptive medications (Bagi et al., 1997). Long-term safety and efficacy 
against fractures are unknown at this time.  
Many women who have first-degree relatives with breast cancer will not consider 
estrogen. For them, selective estrogen receptor modulators (SERM) such as raloxifene 
offer an alternative. SERMs are “designer” drugs that activate the estrogen receptor and 
have estrogenic agonist effects on bone turnover and bone mass (Scott et al., 1999). 
However, SERMs are shown to increase the risk of thromboembolic disease, and lead to 
hot flushes in some patients, which may limit their use. 
Bisphosphonates: Osteoclast endocytosis of bisphosphonate from the bone surface leads 
to FPPS (Farnesyl Pyrophosphate Synthetase) inhibition and osteoclast apoptosis. The 
bisphosphonate class of drugs is approved for the treatment of prevention of osteoporosis. 
Two of these agents, alendronate and risedronate, are currently approved and marketed 
for osteoporosis prevention and treatment. A third oral agent, ibandronate, is currently 
being studied in a novel once-monthly regimen for osteoporosis; and an intravenous 
bisphosphonate, zoledronic acid, is being studied for possible once-yearly treatment in 
women with established osteoporosis. 
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All bisphosphonates are retained over time in the skeleton and may exert long-term 
effects. The biological half-lives of bisphosphonates may vary and depend on the rate of 
bone turnover, potency, and binding affinity of each bisphosphonate to bone. A 
prolonged half-life may be beneficial, because it may prolong a residual effect of the 
agent after discontinuation. On the other hand, prolonged marked suppression of bone 
turnover may have a theoretical influence on the ability to repair bone microdamage. The 
optimal duration of bisphosphonate treatment is unknown.  
Alendronate (Fosamax): in clinical trials, alendronate has been shown to reduce the risk 
of new spinal and hip fractures by 50%. Gastrointestinal problems, such as nausea, acid 
reflux symptoms, and constipation, are the most common side effects. To eliminate these 
side effects, it is encouraged that the medication be taken first thing in the morning with 
large amount of water and not lie down or eat for 30 minutes. Some patients find it 
difficult drug compliance. This medication is usually taken daily or once a week (Black 
et al., 2005).  
Risedronate (Actonel): Results from a recent study showed that daily risedronate use can 
lead to a significant reduction in new vertebral fracture (62%) and multiple new vertebral 
fractures (90%) (Siris et al., 2008) in postmenopausal women with osteoporosis, 
compared with a placebo group. Gastrointestinal upset is its most common side effect. 
Women with severe kidney impairment should avoid this drug.  
Zoledronate (Reclast): this is a new and powerful intravenous bisphosphonate that is 
given once a year (Lambrinoudaki et al., 2008). This can be especially beneficial for 
patients who cannot tolerate oral bisphosphonates or are having difficulty with complying 
with the required regular dosing of oral medications. Its side effect is still unknown.  
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Ibandronate (Boniva): this drug is the most recently FDA-approved bisphosphonate to 
prevent or treat osteoporosis in menopausal women. Ibandronate has been proven 
effective in inhibiting bone resorption at considerably lower doses than other 
bisphosphonates (Mühlbauer et al., 1991, Monier-Faugere et al., 1999). Following long-
term treatment with ibandronate, bone mass, strength and architecture were maintained, 
or even improved (Bauss and Dempster, 2007). The antiresorptive effects of ibandronate 
will be thoroughly discussed in the Chapter 3-5. 
Calcitonins: Calcitonin binds to the calcitonin receptor (CTR) and results in activation of 
multiple pathways including cAMP-PKA, PKC and intracellular calcium, which lead to 
the inhibition of osteoclast resorption. A nasal spray containing calcitonin (200 IU/day) 
was approved in the United States in 1995 for the treatment of osteoporosis in late 
postmenopausal women. Calcitonin is a polypeptide hormone normally produced by the 
thyroid gland. It can be either injected or administered intranasally. Although the effect 
of calcitonin is considered weaker as compare to bisphosphonate, it is generally very well 
tolerated, with rhinitis as the only common adverse event.  
2.1.2 Anabolic agent 
Teriparatide (recombinant human parathyroid hormone): Teriparatide is the only anabolic 
osteoporosis medication. Parathyroid hormone (PTH) is naturally an 84-amino-acid 
polypeptide. In 2002 the FDA approved recombinant PTH (1-34) made by Lilly with the 
brand name Forteo for the treatment of osteoporosis. PTH binds to osteoblasts and 
stimulates osteoblasts to increase their expression of RANKL (Receptor activator of 
nuclear factor kappa-B ligand) and inhibits their expression of Osteoprotegerin (OPG). 
OPG binds to RANKL and blocks it from interacting with RANK, a receptor for RANKL. 
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The binding of RANKL to RANK stimulates these osteoclast precursors to fuse, forming 
new osteoclasts, which ultimately enhances bone resorption and formation. All trials 
show that PTH is highly effective at increasing bone mineral density in the spine and 
throughout the skeleton. Biopsy and bone turnover results indicate that it works by 
stimulating new bone formation on trabecular, endocortical, and periosteal bone surfaces 
by preferentially simulating osteoblastic activity over osteoclastic activity (Dempster et 
al., 2001)..  
PTH currently must be administered by subcutaneous injection, although alternative 
modes of delivery are being investigated. The FDA has approved the use of Teriparatide 
for 2 years in postmenopausal women and men at high risk for fracture. It is 
contraindicated in patients with Paget‟s disease of the bone or patients with bone 
metastases or preexisting hypocalcaemia. The most common side effects associated with 
teriparatide include dizziness and leg cramps. The anabolic effects of PTH will be 
thoroughly discussed in the Chapter 3-5.  
2.1.3 Combination treatment  
Whether the concurrent use of antiresorptive and anabolic agents would produce an 
additive effect by reducing fracture risks is still controversial. For instance, Black et al. 
(2003) and Finkelstein et al. (2003) have reported that a combined therapy of PTH (1-84) 
and alendronate has no synergistic effect on postmenopausal women or aged men, in 
terms of changes in BMD. It was concluded that bisphosphonate (alendronate) impairs 
the ability of parathyroid hormone to increase the BMD at the lumbar spine and the 
femoral neck. However, a recent ovariectomized rodent study discovered that the effect 
of combined administration of alendronate and PTH (1-34) on bone strength is 
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synergistic in the lumbar vertebra and additive in the femur (Johnston et al., 2007). The 
table 2.2 below lists several important studies exploring the effect of combination therapy.  
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Table 2.2. Literature review on different combination treatments of anabolic and antiresorptive drugs (Ratio=Anabolic:Antiresorptive) 
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2.2 Biophysical interventions 
2.2.1 Exercise 
Even though a range of effective drug treatments are available on prescription, there are 
people who cannot tolerate or have low rates of long-term adherence of these drug 
treatments. Thus there is always great interest in any “non drug therapies” for people with 
osteoporosis, though it must be recognized that these are not always supported by good 
research to prove that they reduce the fracture risk. Many patients are encouraged to 
exercise their musculoskeletal system, as bone mineral density can be improved by 
moderate to high intensity weight-bearing physical activity (Bischoff-Ferrari, 2011). 
Postmenopausal women who initiate weight-bearing exercises and/or muscle-
strengthening exercises are proven to help prevent bone loss. A meta-analysis of exercise 
programs indicates that exercisers can gain about 1% bone mineral density vs. their non-
exercised peers over 1 year (Wallace and Cumming, 2000). If that bone density effect 
continues to be addictive each year, it would ultimately produce very substantial effects. 
In another aspect, exercise also benefit on neuromuscular function, coordination, balance, 
and strength, thus reduce the risk of failing. There are different types of exercises which 
are proven effective. Walking modestly increases the load on the skeleton above gravity 
and, and, therefore, this type of exercise has proved to be less effective in preventing 
osteoporosis. This exercise intervention is not specifically designed to maximize loading 
forces to mechanically stress bone and induce changes in BMD, therefore, interventions 
that combine aerobic training with other forms of exercise that provide adequate skeletal 
loading may have greater benefits in improving bone mass among older adults. On the 
other hand, strength exercise seems to be a powerful stimulus for improving and 
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maintaining bone mass during the ageing process. In literature, the best improvements 
seem to be achieved through strength training of high-loading intensities with 3 sessions 
per week and 2–3 sets per session (Zehnacker et al., 2007). Although significant effects 
can be observed after 4 or 6 months in some locations of the body, the efficacy of the 
training programme is greater when it extends for at least 1 year. Multi-component 
exercise programmes of strength, aerobic, high-impact and/or weight-bearing training as 
well as WBV alone or in combination with exercise, may help to increase or at least 
prevent bone mass decline with ageing, especially in postmenopausal women. 
2.2.2 Whole-body vibration 
Not all elderly are able to undertake these high-intensity or weight-bearing exercise. One 
possible alternative intervention is WBV treatment which is performed in a low-impact 
manner with the possibility of producing similar results as the physical exercises (Prisby 
et al., 2008, Wysocki et al., 2011). Recently it has been considered a possible therapy for 
mitigating bone loss and improving muscle performance. In animal studies, vibration 
increases the anabolic (bone building) activity of bone tissue, as well as bone area and 
density (Rubin et al., 2001, Xie et al., 2006, Judex et al., 2007). However, the mechanism 
is not well understood (Rittweger et al., 2010). In WBV therapy, forced sinusoidal 
oscillations produced by motors beneath a mechanical platform transfer energy to a 
human body on the machine. It is believed that WBV induced fast but short stretches in 
muscles and tendon fibers causing increase in muscle power and strength. The increased 
muscle and ligament strength also places the skeleton under greater stress and bone 
responds to this by becoming stronger (Torvinen et al., 2002, Tanaka et al., 2003, 
Kerschan-Schindl et al., 2001). In sum, WBV aims to increase muscle strength with an 
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additional beneficial effect on bone. The vibration is transmitted via a platform on which 
the person usually stands and it is of reasonably high magnitude (0.3-0.8 g) and 
frequency (20-50 Hz) defined by International Organization for Standardization (ISO).  
Table 2.3 shows different protocols of WBV treatment and their effects on the bone 
properties of the animals. Rubin et al. (2002) had demonstrated an osteogenic potential of 
WBV by a study in which the hind legs of ovine were subjected to mechanical vibration 
for 1 year (30 Hz and 0.3g acceleration, 20min/day) resulting in a 32% higher trabecular 
bone volume fraction compared to control. Later on, few ovariectomized rodent studies 
have examined the effect of WBV on osteoporosis specifically. Oxlund et al. (2003) 
found that WBV at 45 Hz, 3.0g for 30 min/ day increased periosteal bone formation rate 
after 90 days. In another study, cortical and medullary areas in WBV group were 
significantly larger than ovariectomized group after 8 weeks of treatment (30 Hz, 3g, 
20min/day) (Rubinacci et al., 2008). However, there are other researcher who claimed 
that no substantial effects of 6 weeks of WBV treatment (90 Hz, 0.3g, 40min/day) on 
tibial bone microstructure and strength in ovariectomized rats were found (Brouwers et 
al., 2010). Similarly, van der Jagt et al. (2012) could not demonstrate any significant 
effects of 10 weeks WBV (45 Hz, 0.5g, 16min/day) on bone loss as a consequence of 
ovariectomy in rats. These studies thus suggest that WBV might have an osteogenic 
effect in ovariectomized animals, but that its effect varies with vibration characteristics 
(intensity, magnitude and duration etc.). The optimal protocol of whole-body vibration is 
still under research. In most of the studies listed below, WBV treatment showed positive 
results, in terms of increment in trabecular bone quantity, bone mineral density. Others 
showed either negative effects or none observable effects. Furthermore, how WBV on 
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ovariectomized rat progresses over long time (more than 12 weeks) has seldom been 
documented. It is of great importance since WBV is often suggested as a life-long 




Table 2.3. Literature review on whole body vibration therapy (:increase, : decrease) 
Author Year Species Parameter s Durations Effects
Flieger 1997 OVX, wistar rats 50Hz, 2g 30min, 60 days
BMD; ultimate strength.
No influence on SHM + vibration
Rubin 2002 Sheep 30 Hz, 0.3g 20min, 365 days BMD; trabecular formation; trabecular thickness




30min, 90 days bone formation rate; endocorticalresorption
Christiansen 2006 Old C57BL/6 mice 
45 Hz, 
0.1 g/ 0.3g/ 1.0 g
15 min, 35 days
 trabecular bone volume in 0.1 and 1.0 g groups;
marrow oestrogenic potential in 0.3 g group
Rubinacci 2008 OVX, SD rats
30 Hz, 
0.6g/ 3g
20 min, 40 days
No observable cortical bone response at 0.6g;
periosteal apposition and endostealresorption at 3g.
Sehmisch 2009 OVX, SD Rats 90 Hz, unknown g 30 min, 35 days bone formation;trabecular microstructure
Brouwers 2010 OVX, Wistar rats 90 Hz, 0.3g 40 min, 42 days No changes in trabecular and cortical structure in tibia




 femoral neck BMD in 0.5g group; femoral diaphysis BMD in 1.5g; 
stiffness and strength in the radius in 0.5g and 1.5g
BV/TV mean values compared to controls.




35 Hz, 0.3g 20 min, 40 days
fracture healing, particularly the early phase;
mineralization and remodelling
Tezval 2011 OVX, SD Rats 90 Hz, 3.9g 15 min, 35 days
strength in femur; trabecular density and thickness.
 rate of bone formation in the periosteal femur
van der Jagt 2011 OVX, wistar rats 45 Hz, 0.5g 16 min, 50 days
no improvements in bone architecture
WBV OVX-induced weight gain
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2.3 Ovariectomized rat model 
The ovariectomized female rat has been extensively used to study osteoporosis. The 
striking resemblance of OVX rat to humans with respect to estrogen deficiency related 
pathophysiology – i.e., increase in bone turnover, bone loss ,and prevention of such by 
estrogen replacement make the OVX rat a gold standard model of osteoporosis. Since the 
OVX rat model effectively demonstrated the skeletal response of known agents such as 
estrogen and PTH in a fashion similar to that in postmenopausal women, it is therefore 
used for evaluation of new therapies for both prevention and treatment of osteoporosis 
(Kharode et al., 2008). 
In this study, bilateral ovariectomy was performed as follows: 
1. Anesthetize rats with an intraperitoneal injection of standard rat anesthesia (45 mg/kg 
ketamine, 8.5 mg/kg, xylazine, and 1.5 mg/kg acepromazine,) from Animal Holding Unit, 
National University of Singapore.  
2. Shave the fur over the dorsal lumbar area; disinfect the skin with Betadine followed by 
an alcohol rinse for three times. 
3. Make a 2-cm skin incision along the dorsal midline (near to the last rib) and through 
the abdominal musculature. 
4. Gently grasp the ovarian fat pad using forceps, expose and remove the ovary (Fig. 2.1). 
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Fig.2.1 incision site and exposure of ovary for ovariectomy in rats. 
 
5. Stitch the muscle with 4.0 absorbable sutures and use stainless steel wound clips to 
close the skin incision. 
6. Sham operation was performed using above steps but without removing the ovaries. 
It was observed in literature that the 3 weeks post-ovariectomy osteoporosis development 
period is adequate for establishing a significant trabecular bone loss in mature Sprague-
Dawley rats (Boyd et al., 2006, Bauss et al., 2002).  
 
  










IBANDRONATE DOES NOT BLOCK 
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3.1 Introduction 
In the previous chapter, different medical treatments were characterized. The first goal of 
this dissertation was to study the density and microarchitectural changes in 
ovariectomized rat bone given treatment of anabolic, antiresorptive and concurrent 
treatment using BMD and μCT measurements. PTH and ibandronate were chosen due to 
several features: As mentioned in Chapter 2, PTH has been shown to have an anabolic 
effect on bone structural properties in animal models (Iida-Klein et al., 2007) and humans 
(Black et al., 2003, Black et al., 2005). It increases bone strength primarily by stimulating 
bone formation. Alternatively, third generation nitrogen-containing bisphosphonates such 
as ibandronate and zoledronate have been successfully used to prevent fracture by 
suppressing bone resorption (Fleisch, 1996, Miller et al., 2005, Lambrinoudaki et al., 
2008). Ibandronate has been proven effective in inhibiting bone resorption at 
considerably lower doses than other bisphosphonates in both rats (Mühlbauer et al., 1991) 
and ovariohysterectomized dogs (Monier-Faugere et al., 1999). Following long-term 
treatment with ibandronate, bone mass, strength and architecture were maintained, or 
even improved (Bauss and Dempster, 2007).  
Whether the concurrent use of antiresorptive agent and PTH would produce an additive 
effect by reducing fracture risks is still controversial. Several studies had been tabulated 
in Chapter 1. In two clinical studies published in 2003, bisphosphonate was found to 
impair the ability of PTH to increase the BMD at lumbar spine and femoral neck (Black 
et al., 2003, Finkelstein et al., 2003). They claimed that this effect may be attributable to 
an attenuation of parathyroid hormone-induced stimulation of bone formation by 
bisphosphonate (alendronate). Nevertheless, additive effects of the same drug 
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combination were observed in other studies (Johnston et al., 2007, Samadfam et al., 2007, 
Cosman et al., 2009). In order to assure the efficacious use of pharmaceutical materials, it 
is essential to investigate the interaction and the net effect of PTH with newly approved 
bisphosphonates. From another aspect, it provides a basic understanding on drug 
combinations for future consequential or alternative administration. As stated in Chapter 
1, we hypothesized that the combination therapy with PTH (1-34) and ibandronate would 
offer an advantage over monotherapy, in terms of bone mineral density combined with 
microarchitectural changes (Campbell et al., 2008) and eventually bone strength. The 
weekly low dosages of both PTH and Ibandronate adopted in this study was selected 
respectively from individual dosing tests, and also served to circumvent the negative side 
effects present in higher doses (Gittens et al., 2004, Bauss et al., 2002). To test this 
hypothesis, we compared the microarchitectural and mechanical changes of OVX rat 
tibiae in the following three treatment groups: PTH (1-34) alone, ibandronate alone and 
combined administration of PTH (1-34) and ibandronate. 
3.2 Methods 
As described in Chapter 1, overall design, proximal tibia bone and rat serum will be used 
to establish the OVX model with drug treatments. Every two weeks, two animals from 
SHM and OVX and three from each treatment groups were euthanized by carbon-dioxide 
asphyxiation. Both right and left tibia bones were harvested, wrapped in 0.9% saline 
soaked guaze and stored at -20ºС until used for the experiments. From the study of 
osteoporotic bone fracture using rat models, the majority of fractures were observed at 
the metaphysis of long bones (Stürmer et al., 2006) where a rapid deterioration of 
trabecular bone occurs (Boyd et al., 2006). Thus, the trabecular-abundant metaphyseal 
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tibia is a suitable region to determine the degree of osteoporosis by bending tests 
(Stürmer et al., 2006, Stürmer et al., 2010) and CT analyses of trabecular bone (Boyd et 
al., 2006) in ovariectomized rat models. 
Micro-computed tomography (µCT) 
The metaphysis region (Fig.3.1 and Fig.3.3A) of the right proximal tibia was scanned ex 
vivo in an upright position with a source to object distance (SOD) of 41 mm and a source 
to image distance (SID) of 339 mm (Teo et al., 2006) using a SMX-100CT μCT scanner 
(Shimadzu, Kyoto, Japan). A 3.29 mm-thick volume of interest (VOI, 200 slices) was 
obtained starting from 1 mm distal to the proximal growth plate (Campbell et al., 2008). 
The resultant grayscale images obtained had an isotropic voxel size of 16.47 µm from 
cone-beam reconstruction (46 kV, 49 µA, scaling coefficient of 50 and averaged 3 times). 
A semi-automated contouring method was employed to select trabecular from cortical 
bone (Bouxsein et al., 2010). In this method, an irregular, anatomic region of interest is 
drawn manually a few voxels away from the endocortical surface (Fig. 3.1). The 
drawback of the semi-automated contouring method is that it is dependent on the user‟s 
judgment and the region can vary among users. 
 
Fig.3.1. Contouring method used to delineate the trabecular bone region. Left: x-ray 
image with ROI (red) in the center; Right: binary image with black region as the selected 
ROI. 
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The grayscale images were segmented using an global threshold of 15.0 % of the 
maximal grayscale value (Laib et al., 2000) using the CT Analyzer software (Skyscan, 
Phil Salmon). Three-dimensional analysis (Teo et al., 2006) were used to assess bone 
volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), 
trabecular number (Tb.N), structural model index (SMI) and trabecular porosity (Tb.Po) 
for the same VOI. Tb.Po calculates the percentage of all the pores (closed and open) 
within the volume of interest. It is also referred to total porosity which is inversely related 
to bone volume fraction.   
Peripheral quantitative computed tomography (pQCT) 
The pQCT scans were carried out with a pixel size of 0.1 mm resolution and a slice 
thickness of 0.5 mm using a StraTEC‟s XCT machine (Research SA+, StraTEC 
Medizintechnik, GmbH, Pforzheim, Germany).  A scout view was performed prior to the 
actual scan to enable exact positioning of the bone specimens. The region of interest 
selected was similar to that used for µCT where the primary effect of osteoporosis was 
expected to be significant. Three types of volumetric bone mineral density (vBMD) were 
obtained, i.e. mean BMD, trabecular density (Tb.BMD) and cortical density (Ct.BMD). 
The thresholds used for separating soft tissue from bone and sub-cortical from trabecular 
bones were 280 mg/cm
3
 and 550 mg/cm
3
 respectively. The mineral density measurements 
from pQCT were taken from 5 adjacent slices within the region of interest for each tibia 
sample, i.e. we measured BMD of 10 slices for each rat and reported the mean values of 
each region of interest. Besides BMD measurement, we have conducted Strength-Strain 
Indices with respect to Y axis (SSIy) to assess the difference in mechanical property of 
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COM group which showed the similar BMD values to the IBN group (Kokoroghiannis et 
al., 2009). The SSI is related to both geometrical properties and cortical density (Ward et 
al., 2005) (Fig. 3.2). 
 
Fig.3.2. A schematic diagram to show the calculation of stability index SSI. 
 
                        3.1 
Where rmax is the distance of voxel from centre; CD is the apparent cortical (bone) density; 
ND is the normal (cortical bone) density (1200 mg/cm
3
); ri is the pixel position from the 
centre; a is the area of a pixel.  
Atypical three point bending test for tibia 
A newly developed testing protocol was adopted for the 3-point bending test of 
metaphyseal tibia (Stürmer et al., 2006). A micro-testing machine (Instron 5848, 
Norwood, MA, USA) with a measuring range from 2 N to 1000 N at a precision of 0.2% 
of the load was used. The speed of the feed motion was 5 mm/s with 5% strain rate and 
the automatic switch-off pressure was set at 300 N. The experiment was programmed to 
stop in case of a strength drop of >20N or a linear displacement of >2mm to avoid 
shattering the tibia specimens. Maximum load (Fmax), yield load (Fy) and stiffness (S) 
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were recorded using „Merlin‟ software. The yield load was determined by the 0.2% offset 
method.  
The tibia were thawed and continuously moistened with isotonic saline solution during 
the test. Each tibia was placed with the three-point contact on the aluminium base, 
consisting of an aluminium block (30 mm wide, 14 mm high, 65 mm long) with the three 
rounded edge free notches (1 mm deep; 2, 3, or 4 mm in diameter) on top (Fig. 3.3B). 
The end of the dorsal proximal tibia (the two condyles) was placed in one of the notches 
(a in Fig. 3.3B). Because of its curved shape, the posterior distal diaphysis was rested on 
the other side of base (b in Fig. 3.3B). During the breaking test, the proximal tibia could 
not slip due to the notch on the base, but it was able to lengthen along the diaphyseal axis. 
The tip of the stamp consisted of an axle-led aluminium roller (8 mm high, 8 mm wide, 8 
mm in diameter). A 2 mm-wide and 1 mm-deep circular notch with rounded edges was 
located in the center of the roller (c in Fig. 3.3B). The roller axle was fixed in a U-shaped 
support, which was connected to the micro tester by an aluminium stem. This positioning 
of the tibia with the custom-made jig ensured its stability during the 3-point bending test 
(Stürmer et al., 2006). 
The movable base was placed so that the distance between the proximal end of the tibia 
(with epiphysis removed) and the center of the roller stamp was 3 mm throughout the test 
to achieve a consistent loading scenario. The stamp was driven down to the ventral 
metaphysis of the tibia until the primary strength of 1 N was reached. After a final visual 
check of the correct tibia position, the breaking test was started.  
  39 
 
Fig.3.3 The tibia specimen in the testing position. (A) μCT rendered image of rat tibia. (B) 
Details of the three-point bending test consisting of the aluminum base and the roller 
stamp. 
 
  40 
Biomarkers of bone turnover 
At week 0, 6 and 12, 300 μL of blood were collected from the lateral tail vein after 
overnight fasting of the rats, 5 days after drug administration. The serum was separated 
by centrifugation and stored at -20°C until analysis. Serum levels of bone formation 
markers, procollagen type 1 N-terminal propeptide (P1NP), and bone resorption markers, 
C-terminal cross-linked telopeptides of type I collagen (CTX), were assessed using 
enzyme-linked immunosorbant assay (Immunodiagnostic Systems Ltd, UK) (Schaller et 
al., 2004, Rissanen et al., 2008) for control, standard and duplicate tests.  
Statistical Analysis 
One-way analysis of variance (ANOVA) was performed by time to determine significant 
difference between different groups for each time point. Similarly, groups were evaluated 
for significant differences over the entire period. Mixed-model and Bonferroni test were 
adopted. The analysis has taken into account that two bones are from the same rat sample, 
using rat as the random factor. With preliminary data, t-test analysis to calculate sample 
size of this study was performed and the statistical significance was assumed at p < 0.05. 
3.3 Results 
Animal weights 
At week 0 of ovariectomy surgery, there was no significant difference in average weight 
among all the testing groups. However, at week 4, the average weight of OVX group was 
significantly higher than that of the SHM group (338.8±18.1 and 294.3±16.6 g) 
respectively, p=0.040). There was a general trend of longitudinal increase in the body 
weight for all the groups, with OVX showing significant weight gain (p=0.009) by week 
2 after surgery compared to SHM at week 8 (p=0.007). For treatment groups, weight gain 
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for animals given PTH, IBN and combined treatment became obvious by 6 weeks 
(p<0.0005), 4 weeks (p=0.006) and 2 weeks (p=0.038) respectively. At the end of study, 
the overall increase in average weight was 29.3% (p=0.013), 54.9%, 46.7%, 52.3% and 
69.5% (all p<0.0005) for SHM, OVX, PTH, IBN and COM groups respectively. 
Micro-computed tomography  
Three dimensional rendering of the tibial metaphyseal region is shown in Fig. 3.4 and the 
corresponding changes in the structural indices determined from µCT scans are shown in 
Fig. 3.5. Within 6 to 8 weeks of OVX surgery, trabecular bone micro-architecture of the 
OVX group exhibited significant difference from the SHM group in all the measured 
indices (BV/TV, Tb.Th, Tb.Sp, Tb.N, SMI and Tb.Po). This is in agreement with 
previous reports (Campbell et al., 2008) on the early detrimental effects of estrogen 
deficiency on trabecular architecture of rats. The results revealed that instead of 
trabecular thinning, the OVX rats are losing whole trabeculae.   
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 Fig.3.4. Visualization of bone loss in a transaction of the tibial metaphysis of an rat from 
each group at the time of surgery, and two, six, ten and twelve weeks following surgery. 
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Fig.3.5. Changes in trabecular morphology measured by μCT. Top row:  Bone Volume 
fraction (BV/TV), Structure Model Index (SMI) and Trabecular Porosity (Tb.Po). Bottom 
row: Trabecular Thickness (Tb.Th), Trabecular Separation (Tb.Sp) and Trabecular 
Number (Tb.N). 
 
The anabolic effect of PTH was apparent on the trabecular architecture. PTH showed 
significant difference from the OVX group in Tb.N and Tb.Sp at week 8 (+43.2%, and -
33.4%, p<0.05) and week 10 (+61.3% and -40.5%, p<0.05) of treatment respectively. At 
week 12, PTH showed higher Tb.N (+71.6%, p=0.024) and lower Tb.Sp (-31.8%, 
p=0.006), as compared to the OVX group. We also observed significant increase in 
BV/TV (+81.8%, p=0.008), with a drop in Tb.Po (-16.2%, p=0.008) compared to the 
OVX group at week 10 and 12.  
It has been shown that reduction in bone volume fraction (BV/TV), loss of trabecular 
number (Tb.N) and increased trabecular separation (Tb.Sp) were all prevented by 
ibandronate treatment in an OVX rat model (Bauss et al., 2002). In this study, 
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ibandronate‟s ability to preserve bone microarchitecture was observed earlier than PTH. 
After week 6, IBN exhibited significant difference from the OVX group in terms of 
BV/TV (+82.9%, p=0.009), SMI (-53.5%, p=0.009), Tb.Po (-19.8%, p=0.009) and Tb.N 
(+75.2%, p=0.016). Tb.Sp decreased significantly compared to OVX group after week 8 
(-38.8%, p=0.015). At the end of the study, BV/TV and Tb.N increased (+78.2%, 
p=0.012) and (+76.9%, p=0.013), while SMI, Tb.Po and Tb.Sp decreased (-21.4%, 
p=0.013), (-15.3%, p=0.012) and (-50.4%, p<0.001) respectively as compared to the 
OVX group. 
The combined COM treatment showed a significant increase in BV/TV (+76.2%, p=0.01) 
and Tb.N (+67.5%, p=0.021) as well as a significantly lower Tb.Po (-18.2%, p=0.010) 
and SMI (-41.1%, p=0.037) as compared to OVX group after week 6. 
Mechanical Testing 
The results of maximum load (Fmax), yield load (Fy) and stiffness (S) of different groups 
from three point bending tests are provided in Table 3.1. Due to the growth of the rats 
involved in this study, Fmax of SHM group increased from 61.2 ± 21.7 N in week 0 to 
104.0 ± 11.0 N at week 12 (+69.9%).  However, there was no significant change in the 
OVX group from week 2 (49.4 ± 11.8 N) to week 12 (48.9 ± 12.1 N). There was a 
significant difference between SHM and OVX groups from the second week after surgery, 
indicating the development of osteoporosis. Within the treatment group, in week 8 and 12, 
Fmax of COM group are significantly higher than that of the IBN or the PTH group. 
However, in week 10, the COM group only shown significant higher Fmax than PTH 
group. At week 12, the percentage increase from OVX in the COM group (168%) was 




Table 3.1. Mechanical property changes of animal groups measured by 3-point bending test. Group averages are represented as mean ± SD. 
 
         Weeks after surgery  
  Groups   0  2  4  6  8   10  12 
Fmax (N) SHM   61.2 ± 21.7 92.7 ± 31.9 
b 
91.8 ± 19.6 
b 
101.5 ± 5.7 
b 
117.0 ± 25.3 
b  
115.5 ± 6.8 
b 
104.0 ± 11.0 
b
 
  OVX     49.4 ± 11.8 
a 
44.2 ± 9.0 
a 
59.1 ± 15.3 
a 
50.5 ± 11.9 
a  
63.1 ± 12.5 48.9 ± 12.1 
a
 
  PTH         64.4 ± 6.7 
a 
57.3 ± 12.0 
a  
67.4 ± 10.1 77.9 ± 17.6 
  IBN         65.0 ± 13.0 
a 
85.3 ± 3.6 
b  
80.3 ± 9.6 86.4 ± 17.4 
b
 
  COM         81.8 ± 3.4 121.5 ± 11.5
b,c,d
107.1 ± 19.2 
b, c 




Fy (N)  SHM   42.4 ± 20.4 42.2 ± 14.5 44.7 ± 9.7 70.7 ± 7.8 72.2 ± 7.1 
b 
75.7 ± 5.8 72.3 ± 14.3 
b
 
  OVX     41.9 ± 20.8 30.3 ± 14.2 48.1 ± 10.5 33.3 ± 13.4 
a 
30.8 ± 7.6 34.7 ± 7.0 
a
 
  PTH         38.8 ± 6.7 
a 
31.1 ± 4.8 43.8 ± 10.4 47.4 ± 9.8 
  IBN         41.7 ± 1.6 
a 
54.6 ± 11.5 51.8 ± 17.5 58.2 ± 20.8 
COM         58.5 ± 15.4 75.4 ± 15.5 
b 
58.8 ± 15.1 78.7 ± 23.1 
b 
 
S (N/mm) SHM   184.8 ± 19.4 167.1 ± 30.9 163.7 ± 33.0 190.3 ± 11.6 209.0 ± 30.9 201.1 ± 19.5 
b 
206.7 ± 31.2 
b
 
  OVX     111.7 ± 35.7 118.4 ± 50.3 112.7 ± 6.8 166.6 ± 30.7 141.8 ± 12.3 
a 
112.8 ± 14.3 
a
 
  PTH         163.9 ± 47.7 153.4 ± 43.2 172.1 ± 16.1 176.6 ± 26.0 
  IBN         158.1 ± 41.2 189.0 ± 25.9 190.3 ± 17.1 180.0 ± 56.0 
  COM         147.8 ± 10.1 253.6 ± 47.3 
b, c 
187.5 ± 15.2 214.0 ± 19.2 
b 
 
a. Significant difference from SHM (p<0.05) 
b. Significant difference from OVX (p<0.05) 
c. Significant difference from PTH (p<0.05) 





There was a significant difference in Fy between SHM and OVX groups in week 12 
(p=0.048). Fy in the OVX group decreased by 18.2% from the surgery to week 12, while 
a sharp increase was observed in the PTH, IBN and COM groups at week 12 (36.6%, 
67.7% and 126.8% respectively). 
From the day of surgery to the end of 12th week, stiffness in OVX has decreased by 
38.9%. On the other hand, in the SHM group, stiffness was relatively stable, from 184.8 
± 19.4 N/mm to 206.7 ± 31.2 N/mm (Table 3.1). From the 10th week, significant 
difference was seen between the SHM and OVX groups (p=0.045). At the end of the 
experiment at week 12, within the three treatment groups the only observed significant 
difference was the COM group compared to OVX (p=0.010). 
Peripheral quantitative computed tomography (pQCT) 
The mean BMD, trabecular density (Tb.BMD) and cortical density (Ct.BMD) from 
pQCT scans for all the groups at different time points are provided in Table 3.2. One way 
ANOVA of the mean BMD of different groups revealed a significant difference between 
OVX (-26.0%, p<0.001) and SHM groups, starting from week 4 to the end of experiment, 
revealing the successful establishment of our ovariectomized rat model. From week 8 
onwards, COM (+18.4%, p=0.015) and IBN (+21.3%, p=0.006) groups showed a 
significant difference from OVX group. At week 10, mean BMD of all treatment groups, 
including PTH (+16.2%, p<0.001) group, were significantly higher than those of the 
OVX group, which demonstrates the effectiveness of PTH and/or IBN treatments. Within 
the treatment groups, COM (p<0.001) group had a significantly higher mean BMD value 
than PTH groups. At week 12, the final week of our experiment, no significant difference 




OVX exhibited a significantly lower Tb.BMD (-27.6%, p=0.002) than SHM from week 2 
onwards. The IBN and COM groups showed significantly higher Tb.BMD (+47.5%, 
p<0.001 and +34.0%, p=0.011) than OVX group from week 8. At the end of experiment 
(week 12), all three treatment groups showed significantly higher Tb.BMD (p<0.05) with 
the IBN group showing the highest value among all treatment groups. We also observed a 
plateau in Tb.BMD for OVX and PTH from week 6 onwards.  
The Ct.BMD of all the rat groups showed an increasing trend with time, indicating the 
continual cortical bone growth. Ct.BMD of the treatment groups (IBN, PTH, COM) 
(p<0.05) was significantly higher than of OVX at week 8. However, after week 8, the 
Ct.BMD of IBN reached a plateau whereas Ct.BMD of PTH and COM groups reached 





Table 3.2. Density changes of animal groups measured by pQCT. Group averages are represented as mean ± SD. 
 
        Weeks after surgery  
  Groups   0  2  4  6  8  10  12 
Mean BMD SHM   631 ± 16 743 ± 14 743 ± 20 
b 
749 ± 9 
b 
786 ± 70 
b
 750 ± 22 
b





) OVX     513 ± 24 550 ± 23 
a 
584 ± 93 
a 
592 ± 14 
a 
573 ± 4 
a 
613 ± 28 
a
 
  PTH         617 ± 25 647 ± 38 
a
 666 ± 29 
a, b 
664 ± 24 
a, b
 
  IBN         632 ± 9  718 ± 49 
b 
675 ± 18 
a, b 
764 ± 29 
b
 
  COM         653 ± 63 701 ± 39 
b 
721 ± 23 
b, c, d 




Tb.BMD SHM   356 ± 19 445 ± 13 
b 
430 ± 9 
b 
392 ± 18 
b 
456 ± 18 
b 
392 ± 59 
b 





) OVX     322 ± 20 
a 
273 ± 27 
a 
193 ± 19 
a 
200 ± 13 
a 
190 ± 15 
a 
179 ± 15 
a
 
  PTH         212 ± 13 
a 
231 ± 20 
a 
218 ± 22 
a 
217 ± 20 
a, b
 
  IBN         255 ± 47 
a 
295 ± 27 
a, b, c 
281 ± 34 
a, b, c 
318 ± 17 
a, b, c
 
  COM         256 ± 56 
a 
268 ± 50 
a, b 
244 ± 30 
a 
272 ± 25 
a, b, c, d 
 
Ct.BMD SHM   1043 ± 3 1038 ± 8 1061 ± 28 1095 ± 26 1090 ± 13 1113 ± 65 1120 ± 22 
(mg/cm
3
) OVX     1026 ± 26 1064 ± 24 1095 ± 30 1110 ± 33 1132 ± 23 1154 ± 16 
  PTH         1124 ± 29 1156 ± 21 
a, b 
1174 ± 13 
a 
1171 ± 16 
a
 
  IBN         1127 ± 23 1161 ± 30 
a, b 
1153 ± 15 
a, b 
1160 ± 31 
  COM         1132 ± 19 1158 ± 10 
a, b 
1182 ± 5 
a, b 
1178 ± 14 
a 
 
a. Significant difference from SHM (p<0.05)
 
b.
 Significant difference from OVX (p<0.05) 
c.
 Significant difference from PTH (p<0.01) 
d.
 Significant difference form IBN (p<0.01) 
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At the 12th week, SSIy values of all groups are presented as follow: SHM = 6.10±0.53 
mm
3
, OVX = 4.44±0.59mm
3
, PTH = 5.43±0.88mm
3
, IBN = 5.70±0.38mm
3
, COM = 7.36 
±0.79 mm
3
. The SSIy of COM group were significantly higher than IBN (p=0.007), PTH 
(p=0.001) and OVX (p<0.001) groups. The percentage increase from OVX in the COM 
group (66%) was greater than the sum of the effects of PTH alone (22%) and IBN alone 






Fig.3.6. Positive linear correlation between maximum load (Fmax) and strength-strain 
index to the y axis (SSIy). 
 
Biomarkers of bone turnover 
The serum levels of bone formation (P1NP) and bone resorption (CTX) biomarkers at 0, 
6 and 12 weeks of different rat groups are provided (Table 3.3). 
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At week 0, the serum P1NP concentration of different groups did not show any 
significant difference. However, at the end of week 12, COM and PTH showed 
significantly higher (p<0.001) levels of P1NP than the rest of the groups. Moreover, 
COM showed 71% significant higher concentration of P1NP than the PTH group 
(p<0.001).  The percentage increase from OVX in the COM group (543%) was much 
greater than the sum of the effects of PTH alone (276%) and IBN alone (-20%) in bone 
formation marker, at week 12.  
At week 0, the serum CTX levels of different groups did not show any significant 
difference. At the end of week 12, a serum CTX level of the OVX group was 113.2% 
(p<0.05) higher than that of the SHM group, indicating higher bone resorption in the 
OVX group than in the SHM group. PTH did not show any significant difference from 
the OVX group. IBN and COM showed a significant decrease in the serum CTX levels as 
compared to the OVX group, suggesting that ibandronate alone or its concurrent 




Table 3.3 Serum levels of bone formation (P1NP) and resorption (CTX) markers. Average concentration is expressed as mean ± SD.  
 
         Week(s) after surgery  
  Groups   0    6    12 
P1NP (µg/L) SHM   19.9 ± 11.6   14.4 ± 7.2   7.8 ± 0.1  
  OVX   17.3 ± 7.9   7.8 ± 1.1   7.6 ± 0.2 
  PTH   19.6 ± 11.9   10.3 ± 0.7   28.6 ± 3.6 
a, b
   
  IBN   13.3 ± 2.1   9.3 ± 2.3   6.1 ± 0.3 
  COM   21.6 ± 3.1   12.9 ± 1.8   48.9 ± 4.0 
a, b, c, d 
 
CTX (µg/L) SHM   21.4 ± 0.1   28.3 ± 5.0   15.2 ± 2.8 
b
 
  OVX   21.6 ± 3.0   43.2 ± 13.9   32.4 ± 4.1 
a
 
  PTH   23.3 ± 9.0   36.6 ± 7.4   41.4 ± 1.8 
a
 
  IBN   20.5 ± 3.8   29.8 ± 11.0   14.3 ± 4.6 
b, c
 
  COM   26.2 ± 0.2   14.1 ± 1.6   17.5 ± 3.6 
b, c 
 
a. Significant difference from SHM (p<0.05) 
b. Significant difference from OVX (p<0.05) 
c. Significant difference from PTH (p<0.01) 
d. Significant difference from IBN (p<0.01) 
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3.4 Discussion 
This chapter investigated the effects of ovariectomy induced osteoporosis and the 
efficacy of the combination therapy of anabolic (PTH) and anti-resorptive (ibandronate) 
drugs in terms of morphological and biomechanical analysis. By using the OVX rat 
model, the changes in bone quality and the efficacy of concurrent treatments were 
assessed through μCT, pQCT, biomarkers and three-point bending tests. The SHM group 
served as a negative control to illustrate normal bone growth over the course of the 
experiment. The OVX group was a positive control group to study changes occurring 
during the development osteoporotic condition following the ovariectomy and to compare 
the effect of various treatments. Differences between OVX and SHM have been well-
characterized from previous studies using μCT (Boyd et al., 2006, Bauss et al., 2002), 
three point bending test (Stürmer et al., 2006). The effect of individual treatment such as 
anti-resorptive treatments: tiludronate (Barbier et al., 1999), ibandronate (Bauss et al., 
2002), have also been extensively studied. Fewer animals were allocated to the OVX and 
SHM group in this study due to the existing results on those groups. In phase 1 study 
(Chapter 3, 4, 5), relatively young rats (12 weeks-old) were used for OVX surgery. There 
are other studies which successfully used 3 months-old rats to investigate the effects of 
estrodiol, testosterone and raloxifene in fracture healing during early osteoporosis 
(Stürmer et al., 2006). Moreover, the effect of vibrational stimulation to prevent bone loss 
in the OVX model were thoroughly investigated using 3-months-old rats (Flieger et al., 
1998, Rubinacci et al., 2008, Sehmisch et al., 2009). Unlike the rabbit osteoporosis model, 
the skeletons of aged rats do not achieve full skeletal maturity and have very low rates of 
remodeling in the cortical bone. Therefore, the trabecular-rich VOI in the proximal 
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metaphysis of rat tibiae are appropriate to study the efficacy of the anti-resorptive and/or 
anabolic drugs in OVX rat model. 
Microstructural and BMD changes in OVX and SHM 
The most significant reduction occurred in bone volume fraction (BV/TV), trabecular 
thickness (Tb.Th) and trabecular number (Tb.N) during the first 6-8 weeks after OVX 
surgery. The trabecular struts became more rod-like and the bone material within the VOI 
becomes significantly porous. These results are consistent with previous studies which 
reported that irreversible microarchitectural changes happen within the first 8 to 12 weeks 
after the ovariectomy (Campbell et al., 2008, Boyd et al., 2006). BV/TV for the SHM 
group used in this study is comparatively higher than in previous studies due to the fact 
that we used 12 weeks-old mature virgin rats as compared to 6-8 month-old retired 
breeders. We observed 57% reduction in BV/TV while previous studies reported a 30-40% 
reduction within the same period of 8 weeks post-ovariectomy (Campbell et al., 2008). 
Bone loss resulting from estrogen deficiency in younger rats is proportionally more 
drastic, mainly because younger rats have denser trabecular bone at the beginning. 
Plateaus were observed from 8 weeks onwards for structure model index (SMI), 
trabecular thickness (Tb.Th), trabecular number (Tb.N) and trabecular density (Tb.BMD) 
for OVX, as previously described by Campbell et al (2008). The leveling off of 
microarchitectural changes was observed even in the treatment groups. Thus, drastic 
structural changes following estrogen deficiency and the leveling off in 
microarchitectural indices illustrate the importance of early treatment in osteoporosis in 
order to prevent further deterioration in bone. 
Beneficial effects of ibandronate 
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Ibandronate inhibits bone resorption and formation by reducing the bone turnover rate 
(Bauss and Dempster, 2007), which helps protect the trabecular microstructure from the 
deleterious effects of bone resorption. Between week 2 and 4 weeks after administration, 
the anti-resorptive effect of ibandronate was apparent in the higher BV/TV and Tb.N and 
lower SMI, Tb.Sp and Tb.Po as compared to OVX group (Fig. 3.5). The beneficial effect 
of ibandronate was also observed from pQCT, which showed a significant increase in 
Tb.BMD after 4 weeks of administration (Table 3.2). Smith et al. also reported a similar 
effect of ibandronate in preventing bone loss and maintaining bone strength in 
ovariectomized cynomolgus monkeys (Smith et al., 2003). Even though the positive 
effects of ibandronate could be observed as early as 2-4 weeks after administration, the 
duration was limited as indicated in the plateau of μCT and pQCT indicies. 
Beneficial effects of PTH 
PTH stimulates bone formation and also bone resorption, effectively increasing bone 
remodeling rate. The net result can produce a catabolic or anabolic effect on trabecular 
bone depending on dosage and frequency of administration (Frolik et al., 2003). The 
comparative higher PTH to ibandronate ratio and intermittent PTH administration used in 
our study exerted a net anabolic effect on BV/TV, Tb.Sp and Tb. Po from the 10th week 
after OVX surgery. Effects of ibandronate on the structural indices were observed as 
early as the 2nd week after the administration of the drug. The fact that the effect of PTH 
was significant only after 6 weeks in rats suggests that ibandronate was more effective at 
preventing the early deterioration of trabecular bone than PTH at similar dosage. 
Beneficial effects of combination treatment 
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Previous studies using alendronate have shown that it may negatively reduce PTH‟s 
anabolic effects on bone tissues (Black et al., 2003, Finkelstein et al., 2003). In our study 
of using the combined PTH and ibandronate treatment, however, significant increase in 
BV/TV and Tb.N while achieving lower SMI and Tb.Po were observed from the 2nd 
week after treatment initiation as compared to individual treatments. The non-blocking 
effect of the concurrent treatments could also be observed in the mean BMD of the pQCT 
results (Table 3.2). This suggests no reduction in PTH‟s anabolic effects when combined 
with ibandronate administration. 
Mechanical testing result 
The results from three-point bending tests were compared to pQCT and µCT analysis to 
evaluate the mechanical property change of the rat tibiae, corresponding to those of 
structural changes. Tibiae treated with either drug or their combination had significantly 
higher Fmax than OVX rats. Among treatment groups, a significant improvement on Fmax 
was observed in the COM group at the end of the study. This means that the combined 
treatment would allow the bone to withstand higher load before fracturing compared to 
mono treatments. This phenomenon is consistent with the higher BMD and Ct.BMD in 
the combined drug treated group as obtained from pQCT. Large standard deviation of Fy 
in the COM group resulted in the loss of statistical significance when compared to other 
treatment groups. This made it difficult to draw a conclusion on early stage microfracture 
in response to each individual treatment. Among treatment groups, COM is the only 
group which showed a significantly higher stiffness as compared to OVX, with the value 
approaching those of the SHM group. It is worth noticing that the sliding support at the 
distal end would possibly introduce an additional friction moment which lies in a 
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direction to increase the force of breaking. However, the moment here is negligible in 
group comparison.  
Biomarker result 
From the biomarker results, we could see that PTH group had significantly higher 
(p<0.001) levels of P1NP than OVX group whereas CTX levels of PTH did not show any 
significant difference from OVX group. This shows that PTH treatment resulted in higher 
bone formation, but had no influence on bone resorption. Meanwhile, IBN group had 
significantly lower (p=0.015) levels of CTX compared to the OVX group but the P1NP 
levels of IBN did not show any significant difference from OVX group. This shows that 
ibandronate treatment resulted in reduced levels of bone resorption, but had no influence 
on bone formation. Overall, the mono-treatment PTH group showed only increased bone 
formation and the IBN group showed only decreased bone resorption, as is consistent 
with previous study (Black et al., 2008). On the other hand, the combined treatment 
group (COM) showed significantly higher (p<0.001) levels of P1NP as well as lower 
(p=0.040) levels of CTX as compared to OVX group. This shows that the concurrent 
treatment has an added advantage on bone mass as it results in the increase in bone 
formation as well as a significant decrease in bone resorption.  
Interestingly, the CTX levels of COM group did not significantly differ from IBN, 
whereas the P1NP levels of COM were significantly higher (p<0.001) than the PTH 
group. This shows that PTH has very little or no effect on the action of ibandronate, 
whereas concurrent administration of ibandronate has a positive effect of inducing the 
action of PTH, thereby increasing bone formation.  
Comparison with literature: drug dosage 
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As a counter additive effect on concurrent administration of both anabolic and anti-
resorptive drugs was shown in previous studies (Black et al., 2003, Garcés and García, 
2006, Finkelstein et al., 2003), a partial positive additive effect was observed in Fmax, 
SSIy and P1NP results in this study. To our knowledge, this is the first study to assess 
concurrent administration of ibandronate (third generation bisphonsphonates) and PTH in 
an OVX rat model. Most of the previous studies that analysed the additive effect of the 
anabolic and anti-resorptive treatments used the second generation bisphosphonates 
(alendronate) along with PTH (Black et al., 2003, Cosman et al., 1998, Garcés and García, 
2006, Finkelstein et al., 2003, Johnston et al., 2007, Rittmaster et al., 2000). While other 
bisphonates require frequent administration to maintain their beneficial effects, Bauss et 
al. (2002) have shown that effect of ibandronate is accumulative and independent on the 
frequency of drug administration. The truncated parathyroid hormone (1-34) used in this 
study was different from full intact parathyroid hormone (1-84). It is speculated that the 
presence or the absence of the C-terminal region of the PTH molecule can affect the 
expression of a biological response (Yamamoto et al., 1994). Since there is no previous 
study of using PTH and ibandronate on SD rats to follow the used dosage, thus, based on 
previous study on the dose dependent effect of PTH (SD rats) (Gittens et al., 2004) and 
ibandronate (Wistar rats) (Bauss et al., 2002), we adopted a relatively high dosage ratio 
of PTH to ibandronate via weekly administration compared to the prevalent therapies for 
the OVX model (Johnston et al., 2007, Samadfam et al., 2007). We believe the effect of a 
drug to those two rats should be quite similar in physical characteristic, which helped our 
decision of choosing drug dosage based on their body weight. The use of weekly low 
dosages of both PTH and ibandronate (with higher PTH to ibandronate ratio) still 
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provided benefits while avoiding negative consequences associated with higher dosages 
(Sato et al., 2002).   
Despite encouraging results, higher dosage and extended duration of exogenous PTH (1-
34) treatment have been reported to produce undesirable side effects (Sato et al., 2002). A 
daily treatment of only 8 µg/kg PTH (1- 34) for one year in OVX rats can result in an 11% 
increase in cortical bone brittleness. Also, PTH (1-34) therapy has been linked with 
hypercalcemia both in animals and in clinical studies (Crandall, 2002). Headaches, 
nausea and back pain were reported with clinical PTH (1-34) therapy. Thus, we reduced 
the PTH (1-34) dosing frequency from daily to weekly as a means of circumventing some 
of these adverse effects. The PTH (1-34) dosage and frequency we adopted are in 
accordance with a comparative study by Gittens et al (2004). The comparison between 
the data in their experiment and the current study suggested that these low doses, 28-40 
µg/kg over 4 weeks, may be close to the threshold for effective dosage for bone mass 
accretion in the OVX rat model. Also, it has been reported that weekly administration of 
PTH increases bone mass as much as daily administration of PTH (Uzawa, 2007). 
Additionally, the high dosage used in previous studies is not clinically relevant. The 
clinical dose of PTH (1-34) used for osteoporosis therapy is 20 µg/day (Finkelstein et al., 
2003, Komatsu et al., 2009). In rats, PTH (1-34) doses of 5 µg/kg/day result in 3 times 
the systemic exposure seen with 20 µg/day in patients (Co Ela, 2002). However, prior 
fracture studies in rats have used doses of PTH(1-34) as high as 200 µg/kg/day (Cipriano 
et al., 2009), calling into question the clinical relevance of the dosage used. These data 
underscore the importance of conducting clinical studies to evaluate the optimized dosage 
of PTH in bone regeneration (Komatsu et al., 2009).  
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The mean BMD results were in agreement with the three-point bending results in terms 
of Fmax, Fy and S, suggesting that BMD measurements can still be used to predict 
mechanical properties of bone. The lack of sufficient statistical significance in our three 
point bending test may be due to the following reasons. The rats used in this study were 
considerably young and their skeleton still growing. Also, three different types of 
fractures (the metaphyseal oblique fracture, the Y-fracture, and the condyle fracture) 
observed by Stürmer et al (2006) may exist in all animal groups, but were not taken into 
account in this study due to limited sample size. 
SSI can predict maximum load 
Besides BMD measurement, we have conducted Strength-Strain Indices (SSI) calculation 
to understand the combined treatment effect of COM group which showed the similar 
BMD values to IBN group. Since SSI is related to both geometrical properties and 
cortical density, the axial SSIy predicts the bending strength with respect to the Y axis 
(the longitudinal axis of rat tibiae). At the 12th week of study, The SSIy of COM group 
were significantly higher than IBN (p=0.007), PTH (p=0.001) and OVX (p<0.001) 
groups. The percentage increase from OVX in the COM group was greater than the sum 
of the effects of PTH alone and IBN alone for SSIy and Fmax, indicating an additive effect. 
As shown in Fig.3.6, the significance and trend is in accordance with Fmax results 
(R
2
=0.8033, p<0.001). A recent study shows that SSIy presents a significantly positive 
correlation with maximum load with a correlation value R=0.846 (P<0.001) 
(Kokoroghiannis et al., 2009). Since SSIy served as a good predictor of Fmax, the SSIy 
values from this study could be served as an explanation to the discrepancy between 
BMD and mechanical testing result. 
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Important factor in drug synergy: Dosage and ratio  
As discussed, we have conducted a pilot study with a relatively low dosage and weekly 
administration of ibandronate and PTH. A higher ratio of anabolic to anti-resorptive 
agent is less likely to inhibit the bone formation function by PTH, which could account 
for the lack of blocking effect by ibandronate used in this study. It also provides a 
possible explanation of why an anti-resorptive agent (ibandronate) is more effective than 
an anabolic agent (PTH) on BMD and mechanical properties. Although the synergistic 
pathway of the two drugs is still unknown in the current study, we believe the partial 
beneficial effect is attributed to the right drug dosage and ratio so that the effect of PTH 
on bone density can be optimized when a potent anti-resorptive agent is used either 
concurrently or alternatively. In previous rodent studies, the effect of concurrent 
treatment of PTH and bisphosphonate was additive at drug ratios of 1:0.3 (Johnston et al., 
2007) and 1:0.2 (Samadfam et al., 2007). On the other hand, negative / blocking effects 
from alendronate occurred at dose ratios of 1:100 (Black et al., 2003) and 1:250 
(Finkelstein et al., 2003) in clinical trials. In this study, we used a PTH to ibandronate 
ratio of 1:0.7 according to tests done by previous studies (Bauss and Dempster, 2007, 
Gittens et al., 2004, Bauss et al., 2002). A threshold ratio of anabolic and anti-resorptive 
agents would be postulated in this OVX model. If the dosage of bisphosphonate went 
beyond the threshold, no beneficial effect would be observed. Below this threshold ratio, 
an increase of PTH dosage might lead to an increase in beneficial effect correspondingly 
(Cosman et al., 2005). Series of ratio dependency experiments and histomorphometric 
studies would be conducted subsequently to better illustrate the mechanism of these 
effects. Apart from dose and ratio, other factors such as rodent appendicular bone effect, 
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nature of drug time course (daily, cyclic, alternation therapies, etc.) could also be possible 
factors that affect the results of this combination therapy.   
3.5 Conclusion 
 Compared to the previous studies which showed impedance from 
bisphosphonates in combination therapy with PTH, this study suggested that 
ibandronate does not block the anabolic effects of PTH in ovariectomized rat 
tibiae. Maximum load, Strength-Strain Indices and bone formation serum markers 
of COM group are significantly higher compared to both mono therapy groups.  
 The effect may be attributed to the proper ratio of anabolic and anti-resorptive 
drugs combined with the appropriate course of treatment. Further exploration of 
these findings would allow us to optimize the ratio between PTH and ibandronate 
and maximize the beneficial effects of the concurrent administration of the two 
drugs in the treatment of osteoporosis. 
  








ALTERATIONS OF BONE VISCOSITY 
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4.1 Introduction 
In Chapter 3, combination therapy of PTH and ibandronate has an additive effect on rat 
tibia in terms of several traditional bone quality parameters.  However, the osteoporotic 
drug effects on nano-level viscoelastic properties were seldom investigated. Nano 
viscoelasticity of bone, which has been of recent concern, mainly arises from the the 
natural viscoelastic response of collagen fiber as a polymer (Ammann et al., 2007, Garner 
et al., 2000, Brennan et al., 2009). During daily life, time-dependent viscoelastic 
deformation occurs in bone as the primary function of skeleton is to bear long-term load 
from bodyweight and muscular activity (Kim et al., 2010, Garner et al., 2000). For a 
better understanding of the pathogenesis and drug efficacy in osteoporosis, timely 
investigation into bone nano viscoelasticity is necessary. 
In this chapter, nanoindentation tests were performed on individual trabeculae and cortex 
of the distal metaphyseal femur. A novel nanoindentation creep test (Kim et al., 2010) 
was adopted to calculate the changes in bone viscosity η, accompanying with 
ovariectomy and drug administration. In comparison and explanation, possible 
concomitant alterations in macro bone geometry, microarchitecture and traditional BMD 
measurements will also be studied in rat femur. As stated in Chapter 1, it is hypothesized 
that osteoporotic bone properties would be influenced by mono or concurrent treatments 
in various aspects. 
4.2 Methods 
As described in Chapter 1, overall design, distal femur bone is used to characterize the 
nano-level viscoelastic change.  
Micro-computed tomography (µCT) 
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Due to several limitations, the previous μCT (SMX-100CT scanner, Shimadzu, Kyoto, 
Japan) is no longer accessible. Thus another μCT machine (Skyscan 1076 scanner, 
Skyscan, Belgium) is adopted here to measure 3D microstructure of distal femur. 
Difference exists in the two μCT machines used in this thesis. Data acquisition from 360° 
around the long axis of the bone sample is required in order to provide a three-
dimensional rendering of the region of interest for further analysis. With the sample 
positioned in between the x-rays source and detector, there are two ways to accomplish 
this. The bone sample has to either rotate on its long axis or the x-rays source and 
detector revolve perpendicularly to this axis. The Shimadzu scanner uses the first method 
while the Skyscan machine uses the second. It is not encouraged to directly compare the 
results from two different methods of scanning. However, group comparison within one 
approach would be still valid.  
Scanning parameters adopted in this Chapter were also modified according to the 
machine. The metaphysis region of the distal femur was scanned ex-vivo in an upright 
position with a source to object distance (SOD) of 121 mm and a source to camera 
distance (SID) of 161 mm using a Skyscan 1076 μCT scanner. A 3.6 mm-thick volume of 
interest (VOI, 200 CT slices) was selected 1mm above distal growth plate (Fig. 4.2) 
(Campbell et al., 2008). The resultant grayscale images obtained had an isotropic voxel 
size of 17.75 µm from cone-beam reconstruction (100 kV, 100 µA, using a 0.5 mm Al 
filter and averaged 3 times). Semi-automated contouring method was again employed to 
select trabecular from cortical bone. The grayscale images were segmented using the 
same threshold of 15% of the maximal grayscale value as last Chapter (Laib et al., 2000). 
Bone volume ratio (BV/TV), bone surface to volume ratio (BS/BV), trabecular separation 
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(Tb.Sp), trabecular number (Tb.N), structural model index (SMI), trabecular thickness 
(Tb.Th) and cortical porosity (Ct.Po) were assessed for the same VOI using the CT 
Analyser program (Phil Salmon, Skyscan). 3D visualization of the VOI using adaptive 
rendering algorithm was done with the ANT program (Skyscan, Belgium).  
Peripheral quantitative computed tomography (pQCT)  
The pQCT scans were carried out with the same parameters described in Chapter 3. The 
mineral density measurements from pQCT were taken from 5 adjacent slices (inter slice 
distance: 0.75mm) at the VOI for each femur sample -- 1mm above distal growth plate 
(Fig. 4.3). Same as Chapter 3, three types of volumetric bone mineral density (vBMD) 
and SSIy were measured. Besides, cortical bone area (Ct.Ar), cortical bone thickness 
(Ct.Th), periosteal perimeter (Ps.Pm), endocortical perimeter (Ec.Pm), cross-sectional 
moment of inertia (CSMI) and were specifically determined at the VOI in this Chapter. 
Nanoindentation testing 
Harvested rat femurs were positioned vertically and embedded in epoxy resin. Over-night 
hardened samples were then metallographically cut to create a smooth surface 1 mm 
above growth plate, perpendicular to the long axis of the bone. Silicon carbide paper of 
grit size 320, 500, 1200, 4000 were consequently used to grind the sample surface. 
Further polishing was done by microcloths with alumina powder of grit size 3µm and 
1µm. Immediately after 16 hours of rehydration with 0.9% saline, the samples were 
subjected to nanoindentation tests using G200 Nanoindenter (Agilent Technologies Inc., 
Chandler, AZ) at room temperature (26ºC). A Berkovich diamond indenter was used for 
all measurements. A total of 30 indents were produced on each sample, four bone 
samples per group. For cortical indentation, 20 indents were evenly distributed on the 
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interstitial bone from medial-lateral area. According to our preliminary test result, this 
area of bone is matured and the value obtained is relatively stable. For trabecular 
indentation, 10 indents were placed in the center of 10 single trabeculae. Data of indents 
from the same sample were averaged and the mean value was used in statistical analysis. 
In this study, Continuous Stiffness Measurement (CSM) and basic creep tests were paired 
to obtain E, H and η, in a single set of test. 
Continuous Stiffness Measurement (CSM):  H and E were continuously obtained in a 
range of depth. It is accomplished by imposing a small, sinusoidally varying signal on top 
of a DC signal that drives the motion of the indenter. This allows the measurement of 
contact stiffness (S) at any point along the loading curve and not just at the point of 
unloading as in conventional measurements (Li and Bhushan, 2002). Superimposed upon 
the quasi-static loading segment was a small oscillating force at 45 Hz. The amplitude of 
the oscillating force, Fo, was continually adjusted in order to maintain the amplitude of 
the resulting displacement oscillation at zo = 2 nm. S was determined continuously during 
loading from the amplitude ratio Fo/zo: 










                         4.1 
Where ϕ is a phase angular lag between the oscillatory force (with frequency ω) and 
displacement; Kf  and Ks are the stiffness of load-frame and support springs; m is mass of 
the indenter.  These parameters can be determined by calibration of the system. E and H 
were then calculated using this continuous measure of S.  
   
      
    
                4.2 
and 
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                      4.3 
P is the load applied to the test surface, and A is the projected contact area at that load 
which can be determined from calibration. Β is a constant that depends only on the 
geometry of the indenter.  
For the purpose of eliminating surface roughness interference in shallow indentation, all 
measurements were taken at the depth range of 800-1000 nm. E and H were determined 
separately for cortex and trabeculae as cortical elastic modulus (Ec), trabecular elastic 
modulus (Et), cortical hardness (Hc) and trabecular hardness (Ht). 
Basic XP creep: This test was adopted to determine the indentation viscosity η. After the 
indenter tip reached the designated displacement, it was held at the maximum load (6 mN) 
for 100 s (Fig. 4.1).  
 
Fig.4.1. Left: A typical indentation load-displacement curve with holding period 
indicated by arrow; Right: Non-linear regression curve fitting of displacement-time data 
in calculation of η (R2 > 0.99). 
 
The indenter tip was then unloaded to 10% of the maximum load and held another 50 s 
for thermal drift measurement. Creep displacement-time curve (the holding period) was 
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fitted using the three element Voigt model as given in Eq. 4.1. η is computed based on the 
curve fitting of creep displacement by non-linear regression. 
                           
                                                                                                                                           4.4 
 
where, h(t) is the indentation creep displacement as a function of time, α is an equivalent 
cone semi-angle (70.3°) to the face angle of the Berkovich indenter (65.27°), E2 is an 
elastic element of the Voigt model and Pmax is the peak load.  
Scanning electron microscopy (SEM) 
After nanoindentation, the samples were polished and etched in a hydrogen peroxide 
solution (35% H2O2) at 40 oC for two hours. The etched specimens were then dehydrated 
immersing in different concentrations (50%, 70%, 90% and 100%) of ethanol solution. 
After being glued on to stubs for SEM, the samples were coated with a thin gold layer. 
Cortical and trabecular bone hydroxyapatite and collagen were examined by scanning 
electron microscopy (FE-SEM, Philips XL series, Netherlands). 
Statistical Analysis 
Statistical analyses were carried out using the SPSS v16 software and the results are 
reported as mean ± SD (standard deviation). One-way ANOVA tests were performed by 
time to determine significant difference between different groups for each time point. 
Similarly, one-way ANOVA tests were also performed by groups to determine significant 
difference within one group over the time period. Bonferroni corrections were used for all 
the comparisons. Statistical significance was assumed at p < 0.05. Correlation of η versus 
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4.3 Results 
Microarchitectural changes in trabecular bone 
Three dimensional μCT rendered images of distal femur region of all the groups at week 
12 are shown in Fig. 4.2. Corresponding changes in the structural indices are represented 
in Fig. 4.4A. 
 
Fig.4.2. µCT rendered image of rat tibia showing the volume of interest (VOI) (left); 
Visualization of bone loss in a transverse secion of the femur metaphysis of a rat from 
each group at week 12 (right), showing prominent trabecular bone loss in OVX group 
and positive effects of drugs in negating the bone loss. 
 
Starting from week 8 post-surgery, trabecular bone microarchitecture of OVX group 
exhibited significant differences from SHM group in all the measured structural indices. 
The effects of IBN and COM treatments in restoring bone microarchitectural indices 
were observed earlier than that of PTH group. Starting from week 8 of our study, IBN 
group began to exhibit a significant deviation from OVX group in BV/TV (+69.7%, p = 
0.041), Tb.N (+40.5%, p = 0.006), Tb.Sp (-34.9%, p = 0.007) and Ct.Po (-21.7%, p = 
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0.011). In COM group, significant differences from OVX group also occurred as early as 
week 8 in terms of Tb.N (+31.5%, p = 0.023), and Tb.Sp (-12.0%, p = 0.035). No 
significant difference was observed between PTH and OVX groups in any of these 
parameters before week 8. At the end of week 12, IBN showed higher BV/TV (+116.4%, 
p = 0.006) and Tb.N (+78.1%, p < 0.001), and lower BS/BV (-27.5%, p = 0.002), Tb.Sp 
(-49.2%, p = 0.016) and Ct.Po (-27.9%, p < 0.001) as compared to OVX group. COM 
also showed higher BV/TV (+120.6%, p = 0.005), Tb.N (+68.0%, p = 0.023) and lower 
SMI (-35.3%, p = 0.049), BS/BV (-30.4%, p = 0.001), Tb.Sp (-37.5%, p = 0.042) and 
Ct.Po (-28.9%, p = 0.015) relative to OVX group. Significant increase in Tb.N (+49.7%, 
p = 0.012) was observed in PTH group as compared to OVX group at week 12. Among 
the treatment groups, a few significant differences were observed. At week 8, IBN group 
showed a higher Tb.N than PTH group (p = 0.050), and a significantly lower Tb.Sp than 
PTH (p = 0.004) and COM group (p = 0.035). At week 12, PTH group had higher 
trabecular BS/BV value than both IBN (p = 0.009) and COM groups (p = 0.004).  
Densitometric changes of cortical and trabecular bone 
pQCT yielded cross-sectional images of five adjacent slices at the VOI of one femur from 
each group are presented in Fig. 4.3. OVX bone specifically showed a less dense 
trabecular mesh and a larger hollow bone marrow region. This is in contrast to the 
healthy state as shown by SHM bone where the bone is highly dense and rich in 
trabeculae. The loss of trabecular bone caused by ovariectomy was observed to be largely 
reversed in COM and IBN groups, partially restored in PTH group. 
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Fig.4.3. Five adjacent pQCT slices from the femur metaphysis of each group at week 12. 
There was evidence of great trabecular bone loss in the OVX group specimens showing a 
larger bone marrow area with less dense (red/yellow) trabecular mesh as opposed to 
highly dense (cyan/white) trabecular bone mesh of SHM specimens. Compared to OVX, 
trabecular bone was better preserved in PTH, IBN and COM specimens along the 
longitudinal axis.   
 
The measured value of mean BMD, Tb.BMD and Ct. BMD are represented in Fig. 4.4B. 
At week 4 post-surgery, a significant decrease in mean BMD (p < 0.001) was observed in 
OVX group as compared to SHM. Significant elevation of mean BMD were found in 
week 8 IBN (p < 0.001) and COM (p < 0.001) groups as compared to both PTH and 
OVX groups. At week 12, mean BMD of COM group approached to that of SHM group 
(p = 1.000) and was higher than other treatment groups (p < 0.001 as compared to PTH 
and IBN). As compared to week 8, there was an observed mean BMD reduction of IBN 
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group at the week 12, resulting in significantly lower mean BMD values as compared 
with SHM (p = 0.002) and COM groups (p < 0.001). At the end of the study, the 
percentage increment from OVX group was greater in COM group (+36.3%) than the 
sum effect of PTH (+6.2%) alone and IBN (+23.0%) alone in mean BMD. 
  
  73 
 
Fig. 4.4. Changes in morphology and volumetric bone mineral density measured by (A) 
μCT: bone surface to volume ratio (BS/BV), bone volume ratio (BV/TV), structural 
model index (SMI), trabecular number (Tb.N), trabecular separation (Tb.Sp), trabecular 
thickness (Tb.Th) and cortical porosity (Ct.Po); and (B) pQCT: mean BMD, trabecular 
density (Tb.BMD) and cortical density (Ct.BMD). 
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In Tb.BMD value, ovariectomy-induced deterioration was observed in OVX group 
starting from week 4. At weeks 8 and 12, IBN and COM groups had significantly higher 
Tb.BMD value as compared to OVX and PTH groups (p < 0.001). SHM group showed 
the highest Tb.BMD (p < 0.001) at the end of 12 weeks. In Ct. BMD, OVX and treatment 
groups showed an increasing trend with time, suggesting continual mineral deposition in 
cortical bone. SHM group showed the lowest Ct.BMD (p < 0.010) from week 8 onwards. 
However, there was no significant difference in Ct.BMD between treatment groups 
throughout the study.  
Geometric and morphological changes of bone 
Geometrical parameter changes of cortical metaphyseal femur of different groups were 
measured (Table 4.1). Statistical significance between SHM and OVX was observed as 
early as week 4 in endocortical perimeter (p = 0.048). At the end of week 12, all the 
geometrical cortical parameters except CSMI showed significant difference between 
SHM and OVX. Although OVX had significant increment in both Ps.Pm (p = 0.001) and 
Ec.Pm (p < 0.001) as compared to SHM, the net result was a reduced Ct.Ar (p = 0.037) 
and Ct.Th (p = 0.001). Within treatment groups, COM group showed significantly larger 
Ct.Ar and Ct. Th than PTH (p = 0.001 and 0.007 respectively) and IBN bone (p = 0.003 
and 0.034 respectively). In Ps.Pm, both COM and PTH group were larger than SHM 
bone (p = 0.003 and p = 0.015 respectively). In Ec.Pm, PTH and IBN were larger than 
SHM (p < 0.001 and p = 0.022 respectively) and were similar to OVX (p > 0.100 for 
both). However, COM group had much smaller Ec.Pm as compared to OVX (p = 0.020) 
and was comparable to SHM (p = 0.105). In CSMI and SSIy analysis, COM was the 




Table 4.1. Geometrical parameters changes of different groups measured by pQCT. Group averages are represented as mean ± SD. 
 
Variables Group 
Weeks after surgery 
0 4 8 12 





) OVX  6.74 ± 0.73  7.28 ± 0.79  6.55 ± 0.54 
a
 
 PTH   7.10 ± 0.42  6.79 ± 0.45  
 IBN   7.73 ± 0.19  6.91 ± 0.27  
 COM   8.42 ± 0.15 
b, c
 8.12 ± 0.62 
b, c, d
 
      
Ct.Th  SHM 0.50 ± 0.05 0.72 ± 0.26 0.65 ± 0.10
  c
 0.62 ± 0.04 
b, c
 
(mm) OVX  0.50 ± 0.08 0.54 ± 0.05 0.50 ± 0.06 
a
 
 PTH   0.50 ± 0.04 
a 
 0.52 ± 0.03 
a
 
 IBN   0.58 ± 0.05 0.54 ± 0.03 
 COM   0.57 ± 0.02 0.63 ± 0.05 
b, c, d
 
      
Ps.Pm  SHM 13.91 ± 1.41 14.36 ± 0.40
 
 14.65 ± 0.48
 
 14.04 ± 0.48
 b, c
 
(mm)  OVX  15.27 ± 1.14
 
 15.10 ± 0.48
 
 14.97 ± 0.33
 a
 
 PTH   15.72 ± 0.75 14.75 ± 0.31
 a
 
 IBN   15.16 ± 0.91 14.54 ± 0.33
 
 
 COM   16.55 ± 0.35 
a, b, d
 14.87 ± 0.23
 a
 
      
Ec.Pm  SHM 10.75 ± 1.51 9.79± 1.95
 b
 10.59 ± 1.07 
c
 10.17 ± 0.64 
b, c, d
 
(mm)  OVX  12.15 ± 1.48
 a
 11.69 ± 0.24 11.89 ± 0.60
 a
 
 PTH   12.55 ± 0.93 
a
 11.54 ± 0.27
 a
 
 IBN   11.50 ± 1.21 11.16 ± 0.52
 a
 
 COM   12.97 ± 0.48 
a













CSMI SHM 9.01 ± 2.56 10.62 ± 0.95  13.49 ± 0.89  9.46 ± 1.25  
(mm
4
) OVX  11.19 ± 2.25  11.25 ± 1.80  9.82 ± 0.88  
 PTH   12.45 ± 1.99  10.03 ± 1.07 
 IBN   12.18 ± 2.56  9.89 ± 0.77  
 COM   16.18 ± 2.00 
b, c, d
 11.82 ± 0.54 
a, b, c, d
 
      
      





) OVX  6.73 ± 0.79  7.00 ± 0.40  6.35 ± 0.42
 a, d
  
 PTH   7.65 ± 0.72  6.65 ± 0.80
 a
  
 IBN   7.88 ± 0.42  7.33 ± 0.24
 b
  
 COM   9.00 ± 0.77 
a, b, c, d
 8.68 ± 0.50 
a, b, c, d
 
 
Ct.Ar = cortical area, Ct.Th = cortical thickness, Ps.Pm = periosteal perimeter, Ec.Pm = endocortical perimeter, CSMI = cross-section 
moment of inertia, SSIy = Y axis Strength-Strain Indices 
a
 Significant difference from SHM (p<0.05); 
 
b
 Significant difference from OVX (p<0.05) 
c
 Significant difference from PTH (p<0.05) 
d
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Fig. 4.5 shows the SEM images of the cortical bone of femur metaphysis for all five 
groups. The cortical bone of SHM group consisted of densely packed nanosized 
hydroxyapatite particles, which seemed to grow tightly on the collagen fiber matrix. 
However, the OVX group had a much looser structure with numerous nanovoids and 
micropores. Since secondary osteon structure is not fully developed in rat skeleton, these 
nanovoids and micropores are the osteocytes residues which exist in primary osteon 
structure. Ibandronate and PTH had different effects on bone microstructure as seen from 
the SEM images. PTH group had a porous bone structure, with visible microfracture at 
the edge of narrow micropores. IBN group showed a denser structure but still with 
rounded pores. COM group had a less porous dense structure, where hydroxyapatite 
seemed to have embedded richly on aligned collagen fiber matrix. Fig. 4.6 shows the 
SEM images of the trabecular bone of femur metaphysis for all five groups. SHM group 
showed a uniform aligned compact structure. However, the differences between the 
treatment groups are not observable. Scale-like fibrils or minerals are randomly 
distributed on the bone matrix. It supports the results of Et and Ht which showed no 
significant differences between different groups. 
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Fig.4.5. SEM surface images of the cortical bone of femur metaphysis from different 
groups of rat, taken at 10,000X magnification. 
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Fig.4.6. SEM surface images of the trabecular bone of femur metaphysis from different 
groups of rat, taken at 10,000X magnification. 
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Viscoelastic analysis of cortical and trabecular bone 
Table 4.2 shows the average values of Ec, Et, Hc, Ht and η of all the groups during the 
course of the study. Ec showed significant difference between OVX and SHM groups, 
starting from week 4 (-21.6%, p < 0.001).  From week 8 onwards, Ec of all the treatment 
groups were significantly higher than the OVX group (p < 0.001).  At the end of week 12, 
Ec of PTH (p <0.001), IBN (p = 0.001) and COM (p < 0.001) were significantly higher 
than that of SHM group. Statistically significant difference was not observed in the Et 
between any of the groups at any time point.  Hc of OVX and SHM group started to show 
a difference from week 4 (p = 0.047) to week 8 (p = 0.009). At week 8, COM group was 
the only treatment group which had significantly higher Hc as compared to OVX (p = 
0.012). This significant difference between COM and OVX was also observed at week 12 
(p < 0.001). Hc of PTH and IBN groups steadily increased and presented significant 
increment from OVX group (PTH: p < 0.001; IBN: p = 0.035) at week 12. In Ht analysis, 
IBN and COM groups demonstrated significantly higher value than OVX group at the 








Weeks after surgery 
0 4 8 12 
Ec SHM 16.74 ± 1.18 17.86 ± 0.54 
b
 17.58 ± 1.27 
b
 17.07 ± 1.04 
b, c, d
 
(GPa) OVX  14.01 ± 1.08 
a
 14.25 ± 1.23 
a, c, d
 14.39 ± 1.06 
a, c, d
 
 PTH   17.52 ± 1.36 
b
 19.06 ± 1.39 
a, b
 
 IBN   17.30 ± 0.80 
b
 18.55 ± 1.07 
a, b
 
 COM   17.61 ± 0.87 
b
 18.89 ± 1.58 
a, b
 
      
Et SHM 13.21 ± 1.06 13.49 ± 0.52 13.68 ± 1.18 13.67 ± 1.23 
(GPa) OVX  12.75 ± 1.12 13.02 ± 1.34 13.15 ± 1.21 
 PTH   13.28 ± 1.14 13.26 ± 1.52 
 IBN   13.10 ± 0.95 13.56 ± 1.18 
 COM   13.45 ± 1.23 14.06 ± 1.54 
      
Hc SHM 0.47 ± 0.06 0.52± 0.03
 b
 0.53 ± 0.06
 b
 0.55 ± 0.07 
(GPa) OVX  0.45 ± 0.06
 a
 0.45 ± 0.05
 a
 0.51 ± 0.05
 c, d
 
 PTH   0.50 ± 0.07 0.58 ± 0.07
 b
 
 IBN   0.47 ± 0.06 0.56 ± 0.04
 b
 
 COM   0.52 ± 0.05 
b
 0.59 ± 0.08
 b
 
      
Ht SHM 0.47 ± 0.07 0.48± 0.06 0.53 ± 0.04 0.54 ± 0.06 
(GPa) OVX  0.45 ± 0.04 0.45 ± 0.02 0.47 ± 0.04
 d
 
 PTH   0.48 ± 0.08 0.52 ± 0.08 
 IBN   0.45 ± 0.05 0.54 ± 0.03
 b
 












η SHM 18743 ± 4264 20235 ± 3354 b 24610 ± 3102 b 29136 ± 4082 b, c, d 
(GPa S) OVX  13326 ± 2807 
a
 20130 ± 4215 
a, c, d
 20385 ± 4045 
a, c, d
 
 PTH   23106 ± 4018 
b
 25088 ± 2925 
a, b
 
 IBN   24613 ± 3840 
b
 25862 ± 3167 
a, b
 
 COM   27236 ± 4223 
b, c




Ec = cortical elastic modulus, Et = trabecular elastic modulus, Hc = cortical hardness, Ht = trabecular hardness, η = viscosity 
a
   Significant difference from SHM (p<0.05); 
b
 Significant difference from OVX (p<0.05); 
c
 Significant difference from PTH 
(p<0.05); 
d
 Significant     difference form IBN (p<0.05) 
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Starting from week 4, significant difference between η of OVX and SHM group was 
observed (p < 0.001). η of OVX group decreased from week 0 to week 4 (-28.9%, p = 
0.011). From week 8 onwards, η of IBN, PTH and COM groups started to be 
significantly different from OVX group (PTH: +14.8%, p = 0.009; IBN: +22.3%, p < 
0.001; COM: +35.3%, p < 0.001). At week 8, COM group had significantly higher η 
value compared with PTH group (p = 0.044) but not with IBN group (p = 0.110). At 
week 12, η of COM group was closer to SHM group (p = 0.153), and significantly higher 
than the other two mono treatment groups (PTH: p < 0.001; IBN: p = 0.014). Correlation 
of η versus Ec was studied (Fig. 4.7). Each data point in the figure represents one 
indentation set on cortical bone in week 12 analysis. Power-law regression trend line was 
plotted individually for each group and the r
2
 value of each group is represented in the 
figure. 
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Fig.4.7. Power-law regression analysis of the relationship between viscosity (η) and 
cortical elastic modulus (Ec) for five different groups at week 12.  
Equations for each group: 
 
OVX:  y = 23.402x
2.527
 ; 
SHM: y = 68.774x
2.1332
  
PTH:  y = 356.44x
1.4337
  
IBN:  y = 99.914x
1.9016
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4.4 Discussion 
In this chapter, we mainly analyzed the effect of PTH, ibandronate and their combination 
therapy on several parameters of bone property (microarchitecture, geometry and 
viscoelasticity) in ovariectomized rat femur. To our knowledge, this is the first study that 
analyzed the viscosity change associated with ovariectomy and administration of drugs. 
The implications from the observed changes in different aspects of bone quality are 
complicated and will be discussed individually. 
Trabecular bone quality  
In trabecular bone architecture and density analysis, both μCT and pQCT results have 
revealed the successful establishment of osteoporotic condition in the femur of OVX rat 
model. Significant reduction occurred in BV/TV, Tb.N and Tb.BMD as soon as 4 weeks 
after ovariectomy surgery. SMI, Tb.Sp and BS/BV results showed that the trabecular 
struts became more rod-like, mean distance between trabeculae and the strut surface area 
have proportionally increased in the OVX group as compared to SHM group. These 
results are consistent with Chapter 3 which also found irreversible microarchitectural 
changes happen within the first 8 to 12 weeks after the ovariectomy in rat tibia. On the 
other hand, treatment groups tended to restore the trabecular microarchitecture closer to 
SHM level. Ibandronate is known to reduce bone turnover rate, mostly by inhibiting bone 
resorption, which helps to protect the trabecular microstructure from the deleterious 
effect of bone resorption (Bauss and Dempster, 2007). At the end of the study, IBN and 
COM groups presented better therapeutic efficacy in restoring trabecular architecture 
(BV/TV, BS/BV, Tb. Sp) and BMDs (mean BMD and Tb. BMD) as compared to PTH 
group. Although PTH is known to stimulate bone formation and resorption (Black et al., 
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2008), the PTH group in this study only yielded an increase in Tb.N at the week 12. This 
could be due to the weekly low dosage of PTH (10μg/kg body weight) that we have 
chosen. According to literature and the previous chapter, the concurrent administration 
can yield a catabolic or anabolic effect on trabecular bone depending on dosage and 
frequency of administration (Frolik et al., 2003, Poole and Reeve, 2005, Yang et al., 
2012).  
Cortical bone quality  
Effects on cross-sectional geometry of cortical bone occurred at a later time period as 
compared to trabecular density and architecture. OVX group had both larger Ps.Pm and 
Ec.Pm than SHM, with a net result of significant reduction in Ct.Ar and Ct.Th. This 
revealed ovariectomy-promoted periosteal bone formation and endocortical resorption, in 
order to compensate the great loss in trabecular density and architecture (Bagi et al., 
1997). Similarly, PTH treated group showed significantly increased Ps.Pm and Ec.Pm 
than SHM at week 12. These geometric changes are in accordance with previous bone 
histomorphometry research (Okimoto et al., 1998), which had also observed that weekly 
hPTH injections at dose of 10 or 90 μg/kg body weight promoted bone formation at 
femoral periosteal envelope and also increased bone marrow area. On the contrary, IBN 
group in this study showed a comparable periosteal perimeter to SHM, and a smaller 
endocortical perimeter as compared to OVX. This preserving effect was also observed in 
other bisphosphonate (i.e., tiludronate, residronate) treated SD rats long bones (Ohnishi et 
al., 1997, Iwamoto et al., 2006). The Ps.Pm of COM group was observed significantly 
larger than SHM, and comparable with OVX bone which has the largest value. In 
addition, the Ec.Pm of COM group was significantly smaller than OVX, and comparable 
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with SHM bone value which is the smallest. Consequently, Ct.Ar and Ct.Th of COM 
group was the largest among treatment and OVX groups. Thus, COM group followed 
neither of the trends observed in monotherapy, but a net gain of bone quantity which 
would have been resulted from increased periosteal bone formation by its PTH 
component and retarded endocortical bone resorption by its ibandronate component. This 
observed additive increase in the cortical bone quantity was reflected in increased CSMI 
and SSIy, which tightly correlates with bone strength (Kokoroghiannis et al., 2009). Thus 
combined therapy offers an added advantage than the mono-therapy in preserving cortical 
bone geometry.  
Nano E and H changes  
In E and H analysis, there were more observable changes in cortical bone than trabecular 
bone. Ovariectomy was found to decrease the Ec and Hc of OVX group significantly as 
compared to SHM group as early as 4 weeks post-surgery. At the end of the study, IBN, 
PTH and COM groups showed increased Ec, Hc as compared to OVX. However, Et and 
Ht of PTH group remained the same as OVX group. These results were similar to 
literature which observed that Hc was found to be positively influenced by PTH effect, 
whereas Ht showed significant decrease (Brennan et al., 2009). It is speculated that the 
remodeling process stimulated by PTH in the trabecular bone leads to a substantial 
deposition of new bone, reducing the hardness of the bone until the tissue matures.  
Accordingly, in our study, a significant increase in trabecular bone number was also 
observed in PTH group, indicating the formation of new trabecular bone without positive 
changes in Ht. On the contrary, with the participation of ibandronate, Ht of IBN and COM 
group was positively influenced as compared to OVX group. One possible explanation 
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would be that the more effective stimulation of type I collagen maturation by 
bisphosphonates can increase the hardness of the newly formed bone as compared with 
PTH alone (Garnero et al., 2008, Boivin and Meunier, 2002). The degree of osteoporosis 
and drug efficacy was often determined at trabecular bone abundant region, rather than 
the cortical bone, density being the key parameter (Stürmer et al., 2006). Accordingly, in 
our study, trabecular bone density showed significant difference between OVX and 
treatment groups whereas cortical density did not. However, the intrinsic properties like 
elastic modulus, hardness, viscosity as well as geometric parameters of cortical bone in 
week 12 treated rats were significantly different from OVX group, revealing therapeutic 
effects on cortical bone. This indicates the importance to assess the effect of osteoporosis 
and associated treatments on cortical bone quality. 
Correlation between E and η 
It was reported in literature that cortical viscosity had a strong positive power-law 
correlation with Ec (Kim et al., 2010). Our result partially supports this claim (Fig. 4.7). 
The positive power-law correlation between η and Ec existed within each group 
individually. However, the increases in η in different groups were not correlated to the 
increases in Ec in same proportion. Firstly, as can be observed from the Fig. 4.7, the 
treatment groups were inclined towards the right side of the graph due to the sharp 
increase in Ec as compared to both OVX and SHM group. On the other hand, the 
increments in η of treatment groups were comparatively moderate. Thus, 8 weeks of drug 
administration to ovariectomized rats was more influential in restoring Ec than η at the 
femur metaphysis. One possible explanation would be the selective modification of bone 
quality by the drugs or the rates at which these drugs may act on bone remodeling, 
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resulting in rapid changes in Ec and delayed changes in η (Brennan et al., 2009). 
Secondly, as compared to OVX group, Ec of IBN, PTH and COM groups increased by 
28.2%, 31.6% and 30% respectively, and η of IBN, PTH and COM groups increased by 
27.4 %, 20.3% and 38.8% respectively. Concurrent administration of drugs restored η of 
the bone better than other two groups whereas their effects on Ec were similar. PTH was 
observed to be less effective in restoring η of the cortical bone. As discussed earlier, it is 
suggested that active bone formation induced by both ovariectomy and the PTH may 
result in increased number of newly formed bone and cement lines with less matured 
collagen (Brennan et al., 2009, Garnero et al., 2008). This can cause more creep 
deformation under constant load and therefore a lower η in rat bones treated with PTH 
only. 
Collagen matrix change  
Mechanical performance of bone is determined by the type and arrangement of different 
structural elements. Hard minerals, as reflected by BMD, contribute to a high strength 
and stiffness to resist compressive stresses and fracture, while compliant collagen fibers 
provide high toughness and viscosity to retard fracture propagation under shear or tensile 
stress (Chang et al., 2011). Based on limited literature, we speculated that the concurrent 
administration of ibandronate and PTH may offer an advantage of promoted bone 
formation by PTH and an effective secondary maturation of collagen matrix lengthened 
by ibandronate (Brennan et al., 2009, Kim et al., 2010, Boivin and Meunier, 2002, 
Garnero et al., 2008). This assumption of matrix changes was further tested using SEM 
surface imaging of cortical bone. The SEM images of the experimental groups implied 
distinct drug effects on cortical bone matrix and their ability to retard fracture 
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propagation. The bone structure of SHM group consisted of densely packed 
hydroxyapatite crystals, which contributes to bone strength and stiffness. Osteoporosis 
can cause porous and randomly aligned matrix structure with poor viscoelastic properties 
(reduced η), as observed in OVX rats. Therefore, microcrack formation and rapid 
propagation are more likely to occur. The ovariectomy induced deterioration of structure 
was alleviated by administration of drugs. Although PTH showed tighter alignment of 
collagen matrix resulting in an increased η, microcracks were also observed which can 
affect the ability of bone to resist fracture propagation. Porous structure in OVX and PTH 
treated groups indicates more active remodeling. IBN showed tighter alignment of 
collagen with lesser pores than OVX group, resulting in an increased η in IBN group. 
Combined treatment was observed to have an aligned collagen matrix structure with 
dense hydroxyapatite crystals which was similar to that of SHM group. The denser 
collagen structure corresponds to higher η values observed in COM and SHM groups. 
Thus, the changes in the collagen matrix structure as observed from SEM images 
complies with corresponding changes in η of the bone indicating that η can be a potential 
indicator of bone quality. These observations from SEM corresponded to the Ct.Po result, 
in which OVX and PTH group presented a higher Ct.Po than other two treatment groups, 
whilst SHM group has the lowest value. 
In addition, according to previous chapter, the serum collagen biomarker (CTX and P1NP) 
analysis had demonstrated that the PTH treatment increased both collagen synthesis and 
degradation, whereas ibandronate treatment decreased bone collagen degradation only. 
However, the combined treatment group exerted an increase in collagen formation as 
well as a significant decrease in degradation. Once the balance has been disrupted, the 
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feature and alignment of collagen fiber and hydroxyapatite crystal properties are also 
expected to change in treatment condition, which correlates with mechanical performance 
of bone by its viscoelasticity to retard crack propagation (Chang et al., 2011). Overall, we 
speculate that combined effect of ibandronate and hPTH on collagen formation and 
degradation in COM group could contribute to the distinct matrix structure as compared 
to other monotherapy groups. We do, however, recognize several limitations of our work. 
First, there are discrepancies between rat and human cortical bone, i.e., the absence of 
harvesian remodeling in rats (Turner et al., 2001). Thus the results observed in this study 
may not have good compliance with clinical observations. Nevertheless, this study would 
shed light on possible viscosity changes associated with osteoporosis and drug 
administration. Although the rats used in our study are matured but young (3 months old), 
treatment efficacy on early osteoporosis phase can be successfully established using them 
(Stürmer et al., 2006, Bagi et al., 1997, Sehmisch et al., 2009). Secondly, it is important 
to note that our data may not translate to combination therapy of PTH with 
bisphosphonates other than ibandronate. 
4.5 Conclusion 
 To conclude, PTH, ibandronate and their concurrent treatment were found to 
partially reverse the ovariectomy induced deteriorations in both trabecular and 
cortical bone. Different treatments had selective effects, especially in preserving 
geometric and nano-level viscoelastic properties of the cortical bone.  
 Similar to the observations in proximal tibia (Chapter 3), the concurrent 
administration of PTH and ibandronate offered an added advantage in mean BMD 
and SSIy of distal femur. Furthermore, it and had a combined positive effect in 
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preserving cortical bone geometry (Ct.Ar, Ct.Th) resulting from a promoted 
periosteal formation by PTH and a decreased endocortical resorption by 
ibandronate.  
 A newer bone quality determinant, viscosity η, has also been studied. Prominent 
increment in η was observed in concurrent treatment group in accordance with a 
denser alignment of collagen fibers and hydroxyapatite crystals with fewer pores. 
A larger scale study is needed to further characterize the relationship between 
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5.1   Introduction 
In the Chapter 4, nanoindentation was used to investigate osteoporosis and treatment 
induced changes in bone nano-level viscoelasticity. In order to further explore the 
relationship of bone strength and macro-level viscoelastic property (loss tangent), DMA 
and mechanical test was mainly used in this chapter. Literature studies (1.2.2) suggested 
that the macro viscoelastic behavior of bone may have a pronounced effect on 
mechanical performance of the bone under dynamic loading. As stated in Chapter 1, it is 
hypothesized that osteoporotic bone macro-viscoelastic properties would be influenced 
by mono or concurrent treatments. 
5.2   Methods 
As described in Chapter 1, overall design, diaphyseal femur bone is used here to 
characterize the macro-level viscoelastic change.  
Peripheral quantitative computed tomography (pQCT)  
All specimens were scanned by pQCT with the same parameters described in Chapter 3 
The region of interest for cortical BMD, bone mineral content (BMC) measurement 
selected was 14-16mm above distal condyle, which covers mid-shaft of each femur. For 
the slice at 15 mm from the distal end, periosteal perimeter (Ps.Pm), endocrotical 
perimeter (Ec.Pm), cortical area (Ct.Ar), cortical thickness (Ct.Th), cross-sectional 
moment of inertia (CSMI) and Strength-Strain Indices (SSIy) on the frontal plane were 
measured.  
Three point bending test of femur 
The mechanical properties of the right femur were measured using three-point bending 
test. A micro-testing machine (Instron 5848, Norwood, MA, USA) with a measuring 
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range from 2 N to 500 N at a precision of 0.2% of the load was used. The bending load 
was applied at 15mm from the proximal end of femur on the posterior surface at a speed 
of 0.05mm/s until fracture, with the anterior surface of the femur face down on supports 
separated by 15mm (shown in Fig. 5.1). The experiment was programmed to stop in case 
of a strength drop of >20N or a linear displacement of >2mm to avoid shattering the tibia 
specimens. The ultimate forces, stiffness (slope of the load-displacement curve) were 
measured as whole bone mechanical properties. The intrinsic biomechanical properties 
such as ultimate stress was calculated using the formula 
ζu = Fu (Lc/4I)                                                                                                           5.1 
where, Fu is ultimate force and L is the span of the support points (15mm). c is the half-
width of mid-shaft in the load direction. I is the cross-sectional moment of inertia. c and I 
are generated from pQCT pictogram. 
 
Fig.5.1. A standard femur diaphysis three point bending test configuration.   
 
Dynamic mechanical analyses 
Dynamic mechanical analysis assesses viscoelastic properties of bone by applying 
oscillating stress σ with angular frequency ω to a material, 
ζ = ζ0 cos ωt                 5.2 
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Resulting strain ε was recorded, 
ε = ε0 cos (ωt - δ)                     5.3 
where δ is the phase angle between stress ζ and strain ε in response to a sinusoidal stress 
ζ (t) as shown in Fig. 5.2.  
 
Fig.5.2. Sinusoidal stress ζ applied to linear viscoelastic material, resulting in strain ε and 
phase lag δ. 
 
The complex modulus of the material under these conditions, E* can be defined as  
E* = E’ + iE”                            5.4 
where E’ is the real or storage modulus (approximated to the Young's modulus )  
E’ = (ζ0/εo) cos δ                            5.5 
and E” is the loss modulus:  
E” = (ζ0/εo) sin δ                           5.6  
The loss tangent, or tan δ, is defined as  
tan δ = E”/ E’                                   5.7  
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tan δ indicates the bone‟s ability to dissipate energy as relative to the energy which it 
stored. DMA assumes that bone is a linearly viscoelastic material. The result is used for 
the purpose of group comparison to assess treatment efficacy.  
In this study, the sample preparation was shown schematically in Fig. 5.3. 36 beam-
shaped bone specimens (11.5 x 1.4 x 0.3 mm) were cut out from left femur posterior 
region under cold water irrigation using a diamond saw (Buehler, Lake Bluff, IL). The 
specimens‟ dimensions are given in Table 5.1. A dynamic mechanical analyzer (DMA 
8000, PerkinElmer, USA) was used to acquire tan δ, E’ and E’’ of cortical femur bone in 
a single cantilever bending mode with 5mm span at 37°C water bath. Each beam was 
tested in a posterior face up orientation. A static load of 500mN and dynamic load of 
500mN was applied in frequency scan from 0.1 to 10 Hz, 25 points per decade.  
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Fig.5.3. DMA sample preparation procedure. (A) Anatomical position of the sample: 
femur diaphysis; (B) Specimen was cut along longitudinal axis and posterior site of the 
femur; (C) Actual size of a typical sample; (D) Testing position on the DMA clamp.   
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Table 5.1. Dimensions of rat cortical bone specimens. The span length for all the 




 Significant difference from SHM (p<0.05)
 
b
 Significant difference from OVX (p<0.05) 
c
 Significant difference from PTH (p<0.05) 
d
 Significant difference form IBN (p<0.05) 
 
Statistical analysis 
For sample dimension, mechanical, geometric and BMD results, statistical analyses were 
carried out using the SPSS v16 software and the results are reported as mean ± SD 
(standard deviation). First, General linear model (GLM) repeated measures was used to 
analyze the effect of different frequencies and treatment groups on tan δ. Frequency was 
set as a within-subjects factor, while group was set as a between-subjects factor. The test 
of within-subjects effects showed that there is no main effect of frequency factor (p = 
0.109). Thus tan δ at each frequency was taken as an independent measurement in the 
later correlation analysis. In fact, constant relationship or trend between tan δ and 
frequency was never observed in literature using bony material (Garner et al., 2000; Les 
et al., 2005). The tests of between-subjects effects showed that there is a significant 
difference between groups (p = 0.017). Thus, one-way ANOVA tests were performed to 
determine significant difference between different groups. Bonferroni corrections were 








SHM 11.48 ± 0.24 1.42 ± 0.03 0.32 ± 0.02 
OVX 11.84 ± 0.06 1.41 ± 0.04 0.32 ± 0.02 
PTH 11.52 ± 0.15 1.41 ± 0.02 0.32 ± 0.02 
IBN 11.56 ± 0.32 1.42 ± 0.03 0.33 ± 0.01 
COM 11.86 ± 0.12 1.41 ± 0.02 0.33 ± 0.03 
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mean values of E’ and tanδ at frequency 0.1, 0.3, 0.6, 0.9, 1, 3, 6, 9 Hz were used as 
dependent variables in a series of one-way ANOVA, examining the effect of treatment. 
In correlation analysis, predictor variables were defined as storage modulus E’, tanδ at 
frequency 0.1, 0.3, 0.6, 0.9, 1, 3, 6, 9 Hz, cortical BMD and cortical area. Strength 
variables were defined as the ultimate force, stiffness and ultimate stress. A non-
parametric Spearman rank-order correlation was performed between the potential 
predictors and the strength variables. 
5.3   Results 
Densitometric and geometric changes of cortical bone by pQCT 
pQCT yielded cross-sectional images of one femur from each group are presented in Fig. 
5.4. The images were taken at 15mm below distal end for each femur bone. Cortical 
BMD, BMC and geometrical parameter changes of cortical diaphyseal femur of different 
groups were measured (Table 5.2). There was no significant difference in Ct.BMD 
between all groups. However, COM group was significantly larger than OVX, PTH and 
IBN group in Ct.BMC analysis (p = 0.035, 0.038 and 0.012 respectively). In terms of 
geometry, COM group showed significant larger Ct.Ar and Ct.Th than OVX (p = 0.038 
and 0.025), PTH (p = 0.037 and 0.009) and IBN bone (p = 0.023 and 0.015). SHM 
showed a significantly larger SSIy than OVX bone (p = 0.047).  
 
Fig.5.4. Visualization of bone geometry in a transverse section of the femur diaphysis of 





Table 5.2. Parameters by pQCT analysis of mid-shaft femoral cross-sectional diaphysis (mean ± standard deviations). 
 






) 6.00 ± 0.09 5.85 ± 0.19 5.83 ± 0.23 5.85 ± 0.39 6.16 ± 0.24 
b,c,d
 
Ct. Th (mm) 0.64 ± 0.01 0.64 ± 0.02 0.64 ± 0.02 0.65 ± 0.03 0.68 ± 0.03 
a,b,c,d
 
Ps. Pm (mm) 11.40 ± 0.06 11.09 ± 0.26 11.15 ± 0.37 11.10 ± 0.78 11.21 ± 0.17 
Ec. Pm (mm) 7.39 ± 0.06 7.03 ± 0.33 7.14 ± 0.44 7.04 ± 0.91 6.95 ± 0.28 
SSIy 4.70 ± 0.21 
b
 4.36 ± 0.21 
a
 4.36 ± 0.36 4.46 ± 0.50 4.55 ± 0.24 
Ct. BMD (mg/cm
3
) 1370.13 ± 11.25 1371.37 ± 4.69 1373.64 ± 16.48 1368.31 ± 10.01 1370.55 ± 8.12 




Ct.Ar = cortical area, Ct.Th = cortical thickness, Ps.Pm = periosteal perimeter, Ec.Pm = endocortical perimeter, SSIy = Y axis 
Strength-Strain Indices, Ct.BMD = cortical bone mineral density, Ct.BMC = cortical bone mineral content. 
a
 Significant difference from SHM (p<0.05)
 
b
 Significant difference from OVX (p<0.05) 
c
 Significant difference from PTH (p<0.05) 
d
 Significant difference form IBN (p<0.05) 
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Three point bending test 
The results of ultimate force, ultimate stress, stiffness and total femur length of different 
groups from three point bending tests are provided in Table 5.3. No difference was 
observed in femur length. However, there was a significant difference between SHM and 
OVX in ultimate force and stiffness (p = 0.001). Ultimate force and stiffness has been 
greatly decreased (-13.89% and -15.17% respectively) due to the ovariectomy surgery. 
SHM group has the highest ultimate force as compared to others (p < 0.050). Within the 
treatment groups, COM has significantly the highest ultimate force compared with PTH 
(p = 0.048) and IBN (p = 0.044) groups. In addition, COM group has higher stiffness as 
relative to OVX and IBN (p = 0.034 and 0.035 respectively), but not PTH (p = 0.105). In 
ultimate stress analysis, COM has a lower value than IBN (p = 0.035). 










SHM OVX PTH IBN COM 
Ultimate force (N) 133.91 ± 7.71 
b,c,d
 115.31 ± 8.75 
a
 119.45 ± 8.69 
a
 118.53 ± 8.40 
a
 129.40 ± 2.97 
b,c,d
 
Ultimate stress (MPa) 229.80 ± 39.16 230.86 ± 9.02 223.75 ± 27.40 246.41 ± 17.50 205.99 ± 19.72 
d
 
Stiffness (N/mm) 358.72 ± 40.65 
b,d
 304.31 ± 44.48 
a
 321.36 ± 37.45 304.80 ± 25.68 
a
 361.11 ± 32.19 
b,d
 




 Significant difference from SHM (p<0.05)
 
b
 Significant difference from OVX (p<0.05) 
c
 Significant difference from PTH (p<0.05) 
d
 Significant difference form IBN (p<0.05) 
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Fig.5.5 and 5.6 shows the tanδ and E’ over 0.1 – 10 Hz frequency range with respect to 
different groups of rats. At frequencies lower than 6 Hz, tanδ of SHM bone was 
significantly the highest (p < 0.050) and OVX bone was the lowest in all five groups (p < 
0.050). Among treatment groups, at 0.3 Hz, COM group has significantly higher value 
than the other mono therapy groups (p < 0.050). Furthermore, at 0.1 Hz COM group has 
higher tanδ than PTH group only (p = 0.018), whilst at 0.6 and 1 Hz, COM group was 
only significantly higher than IBN group (p = 0.035 and 0.018). At other specific 
frequency determined (0.9, 3, 6, 9 Hz), there was no significant difference in tanδ 
between treatment groups. In statistical analysis of E’, SHM was significantly higher than 
OVX and PTH group (p < 0.005), and COM group has shown the largest E’ among all 
the groups (p < 0.050) at all frequencies. 
 
Fig.5.5.The mean tanδ of rat femur diaphysis cortical bone for different groups; error bars 
represent the standard deviation. 
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Fig.5.6. The mean storage modulus (E’) of rat femur diaphysis cortical bone for different 
groups; error bars represent the standard deviation. 
 
Correlation analysis 
Spearman rank-order correlations between the potential predictors and the strength 
variables were determined (Table 5.4). Storage modulus E’ and cortical area was 
positively associated with ultimate force. None of the predictor variables were 
significantly correlated with the ultimate stress. Cortical BMD was associated with 
stiffness of the bone. It was found that at frequency range of 0.9 – 6 Hz, tanδ was 
positively associated with ultimate force.  Furthermore, at 3 Hz, tanδ was also associated 
with bone stiffness. 
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Table 5.4 Spearman rank-order correlations between viscoelasticity, density, bone area 





Macro mechanical properties  
Significant 
values 










0.517 0.261 -0.087  
  0.010 0.218 0.687  
 0.1Hz 0.394 0.283 0.075  
  0.070 0.202 0.739  
 0.3Hz 0.344 0.230 -0.122  
  0.117 0.304 0.590  
 0.6Hz 0.399 0.137 -0.117  
  0.066 0.543 0.603  
Tan δ 0.9Hz 0.534 0.273 -0.159  
  0.010 0.219 0.481  
 1Hz 0.537 0.410 -0.044  
  0.010 0.058 0.845  
 3Hz 0.547 0.437 -0.027  
  0.008 0.042 0.906  
 6Hz 0.493 0.104 -0.047  
  0.020 0.646 0.835  
 
 9Hz 0.411 0.072 0.272  
  0.057 0.750 0.220  
Density Cortical 0.003 0.530 -0.068  
 BMD 0.990 0.011 0.753  
Area Cortical 0.587 0.367 -0.249  
 Area 0.003 0.077 0.240  
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5.4   Discussion 
This chapter demonstrated the effect of PTH, ibandronate and their combination therapy 
on several determinants of bone property (macro-viscoelasticity, geometry and BMD) in 
ovariectomized rat femur diaphysis. These three parameters are independent and their 
correlations with macro bone strength were further characterized using statistical analysis. 
To our knowledge, this is the first study that analyzed the viscoelastic change on OVX rat 
bone associated with administration of drugs using DMA.  
Comparison of DMA result with literature 
Cortical bone is a viscoelastic material. The strain-rate dependence of cortical bone can 
account for up to a fifth of the strength of the human femur during high speed loading 
(Courtney et al., 1994). DMA has been demonstrated as a useful tool to investigate bone 
mechanical properties. It has been proved to be sensitive in distinguishing different 
physiological sites, directions, different nutrition and diseased conditions of the bone 
tested (Abdel-Wahab et al., 2011, Chang et al., 2011, Les et al., 2005, Les et al., 2004). In 
comparison, the tanδ measured in our different treatment groups were in the same range 
as the bone samples with similar dimension reported in literature (tanδ = 0.035-0.1) 
(Abdel-Wahab et al., 2011, Yamashita et al., 2002, Garner et al., 2000). It is close to that 
of the glassy state of polymers (around 0.1) and higher than that of metals (10
-3
 or less). 
Les et al. (2005) has reported that long-term ovariectomy decreases ovine compact bone 
viscoelasticity using DMA. The storage modulus and tanδ was greatly decreased at high 
frequencies in the ovariectomized ovine (5.2% and 83% respectively). In our study, the 
storage modulus and tanδ of OVX rat femur was 21.21% and 34.98% lower than SHM 
significantly at 1 Hz, which is more comparable to the changes in ovariectomized 
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C57BL/6 black mice (23.3% reduction in storage modulus) (Chang et al., 2011). The 
reduction in storage modulus and tanδ indicates the ovariectomized rat femur is less 
efficient at damping oscillatory stresses.  
Viscoelasticity is more sensitive than BMD in detecting osteoporotic change  
According to literature (Les et al. 2005), energy dissipation during an oscillatory stress 
(ΔW/W) is related to δ (Currey, 1988): 
ΔW/W = 2πsinδ               5.2 
Thus, at 1 Hz, the bone sample from our SHM rats was theoretically able to absorb and 
subsequently dissipate 127% as much energy in damping alone as bone sample from the 
OVX rats. It has been proven that the relationship between ash density ρa and the energy 
to yield UY is an exponential one (Les et al., 1994):  
UY = 1.05 ρa
1.83.             
                                                                                                        5.3 
Then this loss of energy absorptive capability at high frequencies might be equivalent to 
that seen in a 13% loss of ash density in a monotonic test. However, BMD changes were 
not seen between groups in our study. Deteriorations in viscoelastic properties which 
unaccompanied by reduction in mineral density could potentially alter bone mechanical 
performance, leading to an increase in fracture risk that would be invisible to clinical 
screen (Les et al., 2005). Similarly, a recent bone fragility study has shown significant 
reductions in storage modulus and tanδ in chronic kidney disease rat femur compared 
with control group, however without any difference in BMD (Iwasaki et al., 2011). 
Drugs/nutrition can potentially restore macro-viscoelasticity  
Nutrition supplements and hormone were found to restore bone viscoelasticity from a 
diseased state. Recently, Chang et al. (2011) has revealed an effective inhibition of 
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osteoporosis in fermented milk supplemented mice assessed by DMA test. The storage 
modulus of bone in ovariectomized mice markedly dropped to 1833 MPa as compare to 
sham operated mice (2125 MPa). However, in fermented milk supplemented mice, the 
storage modulus was as high as 2377 MPa at the end of their study (Chang et al., 2011). 
In our study, although different trends for storage modulus and tanδ were observed for 
different treatment groups with a frequency increase, COM group has both larger storage 
modulus and tanδ than the other two mono therapy groups. 
Geometry change  
Treatment effects on cross-sectional geometry of femur diaphysis were also examined. It 
is worth to notice that while Ct.Th of SHM and OVX bone are similar, Ps.Pm and Ec.Pm 
of SHM were larger than OVX bone as observed in Fig. 5.4. It is suggested in literature 
that with a constant cortical thickness, increasing the diameter of cortex would result in 
an increased strength (Davison et al., 2006). This finding was proved by our mechanical 
test that SHM bone has significant larger ultimate force than OVX bone. Comparing 
treatment groups, although not significant, the Ps.Pm of COM group was observed larger 
than OVX, whilst the Ec.Pm of COM group was smaller than OVX. Consequently, Ct.Ar 
and Ct.Th of COM group was the significantly larger than treatment and OVX groups. 
Combination therapy has offered a net gain of bone quantity which would have been 
resulted from increased periosteal bone formation and retarded endocortical bone 
resorption. A larger diameter of bone with thick cortices is ideal for strength and fracture 
avoidance (Davison et al., 2006). The observed additive effect on the cortical bone 
geometry was in accordance with mechanical test, in which COM has the highest 
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ultimate force among treatment groups. In such a distinctive geometric change in drug 
treated OVX bone, BMC would be more accurate in prediction of overall bone strength.  
Correlation between predictor and bone strength 
Strength of bone is dependent on two main individual physical factors: quantity and 
quality (Chesnut et al., 2001). Bone quantity consists of density and size, which together 
form bone mass. Bone quality consists of structural and material properties. In this study, 
several distinctive surrogates of quantity and quality – BMD, bone area and 
viscoelasticity, and their correlation with bone strength were examined (Table 5.4). Not 
surprisingly, the measured BMD, which reflects hard mineral, was positively associated 
with bone stiffness. However, there was no significant correlation between BMD and 
ultimate force in this study. Storage modulus (analogous to Young‟s modulus in a 
monotonic test) and cortical bone area were found positively correlated with ultimate 
force. Interestingly, it was observed that over 0.9-6 Hz tanδ was also correlated well with 
ultimate force, which covers normal daily activity frequency range (Les et al. 2005, 
Garner et al., 2000). It was widely reported in bovine and human bone studies that a 
relatively minimum in tanδ over a frequency range predominantly contained in normal 
activities. However, the tanδ trends over 0.1-10 Hz in our study were relatively constant. 
This absence of minimum tanδ was also found in ovine sample (Les et al. 2005). 
Different animal model, age or testing condition would possibly attribute to the different 
trend observed. In further study, a wider range of testing frequency would be suggested to 
investigate tanδ change. There were several limitations of this work. First, there are 
discrepancies between rat and larger mammalian animal cortical bone with matured 
harvesian system. Thus the results observed in this study may not have good compliance 
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with observations on larger animals. Nevertheless, this study would shed light on possible 
viscosity changes associated with osteoporosis and drug administration. 
5.5  Conclusion 
 In diaphyseal femur, combination treatment of PTH and ibandronate was 
demonstrated to have a better therapeutic effect on bone than mono therapy, in 
terms of a higher ultimate force, larger cortical area and increased E’ and tan δ.  
 These changes accompanying ovariectomy and treatment would be ignored in 
clinical screening by an unchanged BMD.  
 It is the first time that positive correlations between tanδ and ultimate strength of 
the bone were observed during normal daily activity frequency range (0.9-6 Hz).  
 DMA was demonstrated as a useful tool to assess osteoporotic drug efficacy. 
  





LONG-TERM WHOLE BODY 
VIBRATION IMPAIRS 
OSTEOPOROTIC BONE QUALITY 
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 6.1   Introduction 
In Chapter 3- 5, we have studied the drug effect in osteoporosis treatment in terms of 
bone mineral density, microstructure, geometry and viscoelasticity. The techniques we 
have been practiced for the previous work were optimally developed in OVX rat model. 
Now it is the time to further apply these methods on to the other aspect of treatment – 
whole-body vibration (WBV) therapy. As stated in Chapter 1, we first hypothesized that 
the long-term use (20 weeks) of WBV in ovariectomized rat model can still alleviate the 
bone loss due to osteoporosis. Secondly, according to Wolff‟s law, bone remodeling 
occurs in response to the mechanical stimulus acting on it. The rat skeleton which 
received WBV therapy was expected to response and damp oscillatory stress more 
efficiently. Thus, the whole bone DMA was used here to measure macro-level 
viscoelasticity. WBV may affect the skeleton in different magnitude with respect to their 
different physiological function (weight bearing/non-weight bearing), shape 
(long/short/flat/irregular) and site. WBV has been associated especially with low back 
pain (Lings et al., 2000, Tiemessen et al., 2008). Thus different bone types (tibia, femur 
and spine) were included in this study to thoroughly examine the effect of long-term 
WBV. 
6.2   Methods 
As described in Chapter 1, overall design, proximal tibia and spine bone are used to 
establish the OVX model with WBV therapy, and diaphyseal femur bone is used to 
characterize the macro-level viscoelastic change. Starting from 4th week post-surgery, 
0.3g, 30 Hz WBV was administered to VIB group, 20 min/day for 16 weeks (as shown in 
the Fig. 6.1). A box with lid was used to constrain the rat and to ensure that four limbs are 
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on the platform to receive the whole body vibration. Vertical sinusoidal oscillation was 
produced by motors beneath the platform and transmitted to the rat body. The SHM and 
OVX rats were placed on the vibration platform without vibration for the same amount of 
time as the VIB group. At weeks 20, animals were euthanized by carbon-dioxide 
asphyxiation. Femur, tibia and lumbar vertebral bones were harvested, wrapped in 0.9% 
saline soaked gauze and stored at -20°C until they were used for the experiments. 
 
Fig. 6.1. 20 min/day, 0.3g, 30 Hz WBV was administered to the VIB group 
 
Peripheral quantitative computed tomography (pQCT) analysis 
For the longitudinal study, in vivo PQCT scanning was performed every 4 weeks to 
examine the progress of osteoporosis and treatment effect. Fig. 6.2 shows the operating 
position of a rat in an in vivo scanning. Only rat tibia was scanned due to several 
technical constraints (platform size and rat weight). During the 1 hour scanning process, 
light anesthesia (Ketamine 37.5mg/ml, Xylazine 5mg/ml, 0.2ml/body weight) was 
administered to the rats. 
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Fig. 6.2. In vivo pQCT scans were performed under anesthesia at week 4, 8, 12 and 16. 
 
For the end point (week 20) ex vivo scanning, the harvested tibiae and vertebrae were 
thawed to room temperature and scanned with the same parameters as previous Chapters. 
The region of interest for tibiae was the metaphysis region of the proximal tibia. For 
vertebrae the region of interest was lumbar vertebrae L3. mean BMD, Tb.BMD, Ct.BMD 
and BMC were obtained. The mineral density measurements were taken from five 
adjacent slices within the region of interest for each tibiae sample and three adjacent 
slices within the region of interest for each vertebra sample.  
Compression Test  
After the end point ex vivo pQCT scanning, L3 vertebra was immediately prepared for 
compression testing. The vertebral pedicles were dissected out with care to avoid any 
damage to the cortical shell. Using a low-speed precision saw (Isomet, Buehler, Lake 
Bluff, IL, USA) under constant water irrigation, the cranial and caudal ends including the 
growth plate were removed to obtain planoparallel surface. After sawing, the vertebral 
height was measured using calliper and found to be approximately 4mm. The test 
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specimen was mounted between two aluminium plates. The mechanical resistance to 
failure was tested using a micro-testing machine (Instron 5848, Norwood, MA, USA) 
with a measuring range from 2N to 1000N at a precision of 0.2% of the load was used. 
The deformation rate was applied in the craniocaudal direction and set at 
0.033mm/second (Ikeda et al., 2001, Barak et al., 2010). Load-deformation curves were 
recorded continuously. The specimens were loaded to failure and the whole process 
would be automatically terminated when the load reached 200N (Fig. 6.3). From the 
load-deformation curve, maximum load, stiffness and energy dissipation (work to 
fracture) was obtained. 
 
Fig.6.3. Vertebra sample placed on the compression test device  
 
Whole bone dynamic mechanical analysis (DMA) 
Femur bone was used in DMA test. DMA has been used to characterize cortical bone 
chip viscoelastic properties in Chapter 5. Here in this Chapter, the configuration is 
modified for conducting the whole bone DMA. Before the analysis, the thickness and 
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width at the centre of each femur were measured. Then the femur bone sample was then 
placed in a dynamic mechanical analysis device (DMA 8000, PerkinElmer, Norwalk, CT) 
at 37 °C water bath in a 3-point bending configuration. Fig. 6.4 shows one sample in the 
testing position. Frequencies of scanning ranged from 0.1 to 10 Hz. The test was 
conducted under displacement control. Storage modulus E’ and tan δ were measured for 
each sample.  
 
Fig.6.4. Femur sample placed on the DMA device with 3 point bending configuration 
 
Statistical Analysis 
Statistical analyses were carried out using the SPSS v16 software and the results are 
reported as mean ± SD (standard deviation). One-way ANOVA tests were performed by 
time to determine significant difference between different groups for each time point. 
Bonferroni corrections were used for all the comparisons. Statistical significance was 
assumed at p < 0.05. 
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6.3   Results 
Animals 
There was no significant difference in the weight of the rats in each group at week 0. 
However, at the end of the experiment, there were significant differences in amount of 
weight gain between SHM and OVX group (p = 0.012) as well as VIB and OVX group 
(p = 0.037). Compared with the baseline measurement, OVX group had the highest 
weight gain (47.75%), followed by VIB group (26.40%). SHM group had the lowest 
weight gain (15.54%) (Fig. 6.5). 
 
Fig.6.5. Percentage change in body weight. Mean value with standard deviation error bar 
were presented for each group. *:p < 0.05 from OVX. †: p < 0.01 from OVX 
 
Densitometric changes of trabecular and cortical bone 
Both in vivo and ex vivo pQCT rendered images were shown in Fig. 6.6. Highly densed 
bone tissue were shown in cyan and white color, whereas less densed bone tissue were 
presented in yellow and red. According to Fig. 6.6., SHM was rich in trabecular bone in 
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both tibia metaphysis and lumbar. This is in contrast to the VIB and OVX bones where 
the bone is less densed and poor in trabeculae connection.  
 
Fig.6.6. Visualization of bone loss in (A) longitudinal in vivo PQCT image of tibial 
metaphysis at week 4, 8, 12 and 16; (B) ex vivo PQCT image of tibial metaphysis at end 
point week 20; (C) ex vivo PQCT image of lumbar vertebral L3 from each group. 
 
Table 6.1 showed the quantitative changes in BMD and BMC in different groups at week 
4, 8, 12, 16 and 20. Between OVX and SHM group, there was significant difference in 
tibia mean BMD starting from week 4 after surgery till the end of the study. At the end of 
week 20, OVX and SHM had significant differences in tibia mean BMD (p = 0.007), 
tibia Tb.BMD (p < 0.001), and lumbar mean BMD (p < 0.001). This is in accordance 
with the previous studies which had shown an ovariectomy induced significant trabecular 





Table 6.1. BMD and BMC changes of different groups measured by pQCT. Group averages are represented as mean ± SD. 
  
 




Weeks after surgery  





SHM 651.48 ±  6.76 645.50 ± 16.27  640.56 ± 20.74  642.35 ± 8.43 645.57 ± 42.75 572.04 ± 0.66 
OVX 620.25 ± 12.41 608.50 ± 23.73  598.33 ± 10.42  593.50 ± 15.54 592.81 ± 16.38 535.78 ± 11.60 
VIB 614.37 ± 10.23 591.43 ± 25.50 598.10 ± 7.07  589.67 ± 5.25  590.80 ± 18.18 468.21 ± 14.55 





SHM 244.22 ± 15.14 264.53 ± 25.02 296.87 ± 10.23 320.62 ± 22.04 310.50 ± 48.87 228.91± 21.01 
OVX 234.57 ± 26.34 231.33 ± 16.16 209.33 ± 32.25 193.50 ± 34.65 203.43 ±13.80 244.57 ± 25.16 
VIB 232.33 ± 18.77 244.22 ± 15.14 215.02 ± 14.14 210.71 ± 11.31 206.67 ± 26.90 209.83 ± 11.83 





SHM 1097.44 ± 11.39 1098.20 ± 31.11 1120.37 ± 27.49 1131.18 ± 34.35 1127.17 ± 12.86 1032.77 ± 26.91 
OVX 1081.65 ± 15.60 1099.67 ± 23.71
 
 1139.21 ± 21.36
 
 1150.33 ± 14.47 1144.51 ± 20.85 1011.93 ± 16.40 
VIB 1099.67 ± 28.36 1128.25 ± 24.79 1088.75 ± 64.03 1182.05 ± 23.43 1144.32 ± 29.90 989.95 ± 26.54 
        
BMC 
(mg/mm) 
SHM 13.36 ± 0.43 13.42 ± 0.59 13.39 ± 0.81  13.26 ± 0.35 13.26 ± 0.64 17.79 ± 0.97 
OVX 13.19 ± 0.25 12.91 ± 0.52  13.15 ± 0.17  13.31 ± 0.44  13.30 ± 0.54 16.29 ±1.09 
VIB 13.07 ± 0.65 12.57 ± 1.05 12.35 ± 0.49  12.55 ± 0.63 12.47 ± 0.36 14.25 ±0.40 
 
  121 
In the comparison between OVX and VIB tibia bone, there were no significant 
differences in tibia mean BMD and tibia Tb.BMD (p > 0.05). In addition, there was a 
significant reduction in tibia BMC of VIB group as compared to OVX (p < 0.001). 
Furthermore, VIB vertebrae bone has significantly lower mean BMD, Tb.BMD and BMC 
than OVX group (p < 0.001, p = 0.028 and p = 0.005 respectively).  
Vertebrae Compression Testing  
Fig. 6.7 shows the results of the L3 vertebral compression test, in terms of maximum load, 
stiffness and energy dissipation. SHM group has the highest value of maximum load 
followed by OVX then VIB groups. VIB vertebrae has significantly lower maximum load 
as compared to OVX group (p = 0.012). There was no significant difference found in 
stiffness between OVX and VIB (p = 0.081). However, VIB group was significantly less 
stiff as relative to SHM (p = 0.035). The difference in maximum load and stiffness 
between each group can be clearly observed from the typical load-displacement curve. 
Energy dissipation -- area under the curve, is also determined. Both OVX and VIB 
groups had significantly lower energy dissipation as compared to SHM group (p = 0.018 
and 0.001 respectively).  
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Fig. 6.7. Maximum load, stiffness, typical load-displacement curve and energy to failure 
in compression test of L3 vertebrae. Mean value with standard deviation error bar were 
presented for each group. *p<0.05 versus OVX rats. 
 
Dynamic mechanical analysis 
Fig. 6.8 shows the whole bone DMA results of different rat groups. The averaged values 
and significance were measured at 1 Hz frequency (within daily activity frequency range). 
Although not significant, SHM bone has the highest E‟, followed by VIB and OVX group. 
In tan δ analysis, SHM was found significantly higher than OVX and VIB group (p = 
0.036), while there was no difference found between OVX and VIB (p = 0.125). In 
summary, 16 weeks of WBV therapy did not render any enhancement in storage modulus 
or damping efficiency (tan δ) of the ovariectomized rat femur. 
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Fig. 6.8. Storage modulus (E‟) and tan delta measured at 1 Hz by dynamic mechanical 
analysis (DMA). Mean value with standard deviation error bar were presented for each 
group. *p<0.05 versus OVX rats. 
 
6.4   Discussion 
Currently, low-impact WBV platform has been introduced commercially as it is claimed 
to reduce bone loss due to osteoporosis. In this chapter, the long-term effects of WBV 
were examined using in vivo pQCT scanning allowing longitudinal follow-up of the bone 
densitometry in proximal tibia of individual rats for 16 weeks treatment. In order to 
investigate the capability of mechanical stimuli, in the form of WBV treatment, to 
reinforce the integral damping efficiency of the treated bone when encountered with 
oscillatory stress, the whole bone DMA test were carried out on femur bones. In 
vertebrae of the OVX and VIB rats where severe bone loss was revealed by ex vivo 
pQCT scanning, compression test was conducted to further elucidate the probability of 
the spine fracture. 
Justification of the 30Hz, 0.3g regimen   
The optimal vibration protocol (frequency, amplitude) to prevent bone loss is not yet 
determined (Table 2.3). In this study, we adopted 30 Hz and 0.3g regimen in OVX rats 
due to several reasons. First, similar regimens in rodents (32-35 Hz, 0.3-0.5g) were 
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shown to have successfully increased bone mineralization and strength (Shi et al., 2010, 
Wenger et al., 2010). Second, ISO 2631 (1985) standard had defined a safety vibration 
range for human: 0.3-0.8 g in 20-50 Hz. Beyond this range, acute discomfort may arise 
from: 1. focal pain in muscle and joints, especially in spine; 2. Alterations in visual 
perception and tracking. Thus 30 Hz and 0.3g whole body vibration, which proven to be 






). We do notice that 
there were more positive results reported from literature with vibration protocols beyond 
45 Hz and 1g in rodents (Sehmisch et al., 2009, Tezval et al., 2011, Brouwers et al., 2010, 
Christiansen and Silva, 2006, Van der Jagt et al., 2012, Flieger et al., 1998). Despite of 
the encouraging result, the protocols would never be applicable for human, calling into 
question the clinical relevance of these data.  
WBV reduced weight gain   
OVX rat has a significantly larger weight increase (47.75%) as compared to SHM rats 
(15.54%). The effect of ovariectomy on hyerphagia and subsequent fat tissue gain has 
been extensively studied (Jiang et al., 2008). However, the effect of WBV on reduction of 
weight gain (26.40%) due to ovariectomy was unexpected in the current study thus the fat 
tissue were not preserved. A recent study has also revealed a similar effect on weight gain 
in WBV rats (Van der Jagt et al., 2012). In their study, the averaged weight gain of OVX 
rats was 88.5 g compared to 62.7 g in the delayed vibration group (p = 0.03). One 
possible reason for reduction of weight gain can be the inhibition of terminal 
differentiation of adipocyte (fat cells) progenitor by loading stimuli. It was reported that 
in the process of differentiation, the PTH/PTHrP signaling pathway were affected 
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(Menuki et al., 2008). Hence, vibration treatments might be beneficial to reduce post-
menopausal weight gain in human. 
WBV had no effect on long bones, but deteriorates lumbar bone quality   
In this study, the rats were given 0.3 g, 30 Hz and 20 min/day WBV therapy based on the 
protocol used by Rubin et al., (2002) which showed increased BMD and trabecular 
formation. However, according to pQCT results on rat tibia, there were no significant 
differences observed in mean BMD, Tb. BMD or Ct.BMD between OVX and VIB bones. 
However, BMC of the VIB tibia bone was significantly lesser than OVX which reveals a 
decrease in bone area of the VIB group. The current study shows that vibrations are not 
proven in alleviating the loss of bone caused by osteoporosis in rat tibia. It is in 
accordance with the experiment results from Brouwers et al (2010), in which vibration 
was not shown any sufficient preserving effect on the proximal and metaphysis of rat 
tibia. In vertebrae densitometry analysis, VIB group even experience significantly bone 
loss in mean BMD, Tb. BMD and BMC as compared to OVX vertebrae bone which can 
be visualized in Fig. 6.6. The result indicated that not only the unit density was greatly 
decreased, but also a reduction in amount of existing bone in vibration treated rat 
vertebrae. The reduced BMD and BMC in vertebrae of VIB rats were reflected by 
compression test result of L3. Bone samples from VIB group had comparable stiffness 
and energy dissipation ability as OVX, while its maximum load was even significantly 
lower than that of OVX group. It indicates that after long-term vibration treatment, the rat 
vertebrae may become less able to bear load when fracture. It is worth notice that in 
longitudinal study, although not significant, VIB tibia had comparably larger Tb. BMD 
than OVX at week 8.  
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Comparison with literature 
The result is similar to a previous study done by Oxlund et al., (2003) which found that 
ovariectomized rats that receive WBV has a higher BMD in the femur and the tibia 
compared to non-vibrated controls after 5 weeks of WBV but not after 12 weeks. 
Therefore, WBV therapy may not be beneficial but even detrimental to the vertebrae 
BMD after 16 weeks of treatment with the current protocol. It was found in rabbit 
annulus cells that vibratory loading had suppressed several collagens which function in 
bone remodeling as well (Yamazaki et al., 2002). Thus, one possible explanation for why 
vibration had a negative effect on spine in our study would be the reduction in functional 
collagens. Western blot of collagens excreted from bone cells will be characterized in 
future work to further elucidate the mechanism. The discrepancy in our finding and other 
studies may attribute to different vibration parameters used (frequency, magnitude), or 
duration of the regimen. To date, the optimal protocol for WBV therapy has not been 
explored thoroughly. Since not all WBV regimens would alleviate the bone loss in 
osteoporosis, prescription or recommendation of such a therapy should be more careful 
and depending on follow-up response from the individuals. 
6.5 Conclusion 
 The WBV treatment can significantly reduce postmenopausal osteoporotic weight 
gain. 
 In this pilot study, the effect of WBV treatment on ovariectomized rat bone was 
evaluated using in vivo and ex vivo BMD measurement, compression test and 
DMA analysis. While no beneficial effect of WBV was found in BMD of tibia, 
vertebrae BMD and maximum load was significantly reduced in WBV treated rats.  
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  Since the optimal parameters were still under research, WBV should not be 
recommended for long-term usage. 
  





CONCLUSIONS AND FUTURE 
DIRECTIONS 
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7.1 Conclusion  
The primary objective of this study was to examine whether there is a beneficial effect of 
PTH and ibandronate combined therapy in the ovariectomized rat bone.  A total of 11 
indices showed a significant difference between sham and ovariectomized groups, 
suggesting the successful establishment of osteoporosis in the rat model. Maximum load, 
strength–strain indices (SSIy) and serum bone formation markers of combination group 
were significantly higher than both monotherapy groups. Compared to the previous 
studies (Finkelstein et al., 2003, Black et al., 2003) which showed impedance from 
bisphosphonates in combination therapy with PTH, our study revealed that ibandronate 
does not block the anabolic effects of PTH in ovariectomized rat tibiae. The additive 
results of combination therapy can be attributed at least partially to the proper ratio of the 
two drugs. With the proper ratio of anabolic and anti-resorptive drugs, the effect could be 
more pronounced. These findings provide valuable information regarding the potential of 
combination drug in the treatment of osteoporosis. However, it should be point out that, 
the most beneficial ratio of the two drugs was not optimized in this study. Further 
research is therefore needed to optimize the ratio between PTH and ibandronate and 
maximize the treatment effects of the concurrent administration.  
Strength of bone is dependent on two main individual physical factors: quantity and 
quality (Chesnut et al., 2001). Bone quantity consists of density and size, which together 
form bone mass. Bone quality consists of structural and material properties. Thus, besides 
BMD, viscoelastic properties (viscosity, elasticity, tan δ etc.) of bone are also crucial 
determinants of bone strength. Viscoelastic response of ovariectomized rat bones and 
treatment effect was further examined using nanoindentation and DMA test. Firstly, in 
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the nanoindentation test, ovariectomy induced deterioration in viscosity and elastic 
modulus was observed in cortical bone. PTH, ibandronate or its concurrent treatment can 
effectively reverse ovariectomy induced deteriorations in both trabecular and cortical 
bone. Different drugs had selective effects especially in preserving geometric and 
viscoelastic properties of the bone. The concurrent administration of PTH and 
ibandronate was shown to offer an added advantage in preserving mean BMD and had a 
positive effect on cortical bone geometry, resulting from an increased periosteal 
formation and a decreased endocortical resorption. Viscosity (η) was prominently 
restored in combined treatment group. It is in accordance with an observed denser 
alignment of collagen fibers and hydroxylapatite crystals matrix with fewer pores, which 
may play an important role in hindering fracture propagation.  
Secondly, DMA measurements on identical cortical samples from control and drug 
treated diaphyseal femur bone were conducted to compare with the bending test on the 
same region of interest. The BMD of diaphyseal cortical femur bone samples did not 
show any difference between groups, whereas combination treatment was demonstrated 
to have a better therapeutic effect on bone than mono therapy, in terms of a higher 
ultimate force, larger cortical area and increased E’ and tan δ. This indicates that these 
viscoelastic changes accompanying ovariectomy and treatment would be ignored in 
clinical screening by an unchanged BMD value. In order to translate these unseen 
changes into fracture risk, BMD, bone area and viscoelasticity and their correlation with 
ultimate bone strength were further examined. Not surprisingly, the measured BMD, 
which reflects hard mineral, was positively associated with bone stiffness. However, 
there was no significant correlation between BMD and ultimate force in this study. E’ 
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and cortical bone area were found positively correlated with ultimate force. Interestingly, 
it is the first time that positive correlations between tan δ and ultimate strength of the 
bone were observed during normal daily activity frequency range (0.9-6 Hz). Results 
from this study demonstrated that DMA is a useful tool to assess osteoporotic drug 
efficacy. The measured tan δ can be another possible surrogate for measuring bone 
strength. 
A comparison of results from different bones between Chapter 3, 4, 5 by shared 
techniques would be meaningful since same group of rats was used: 
CTs: BMD values and microarchitectural indices from distal femur and proximal tibia are 
similar since they both are metaphysis region of long bone. Geometrical change of 
cortical bone is more prominent in metaphysis than diaphysis region. The drop of Tb. 
BMD in ovariectomized rat bone is mainly due to the changes in Tb.N and Tb.Sp, not 
because of Tb.Th. This implies the disappearance of whole trabeculae.  
Mechanical and viscoelastic tests: End point three-point bending of tibia and femur both 
showed more significant differences between groups in Fmax than stiffness.  Treatments 
had effect on the fundamental nano-level viscoelastic properties (i.e., η) as well as the 
apparent macro-level viscoelasticity (tan δ). BMD and mechanical properties are in 
consistency only in metaphysis which is abundant in trabecular bone.  
In addition, BMD, mechanical and viscoelastic properties in WBV therapy treated 
ovariectomized rat were investigated in Chapter 6. Based on the reported fact that high 
bone formation rates in long bones and vertebrae of ovariectomized animals after WBV 
(Rubin et al., 2002, Oxlund et al., 2003, Sehmisch et al., 2009, Tezval et al., 2011, 
Wenger et al., 2010, Christiansen and Silva, 2006), we assume that these pronounce 
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effects of WBV would last for long-term usage. In this pilot study, an in vivo pQCT and 
whole bone DMA were adopted to explore the longitudinal and endpoint effects of WBV. 
However, no substantial effects resulting from 16 weeks of low-magnitude, high-
frequency vibration treatment (30 Hz, 0.3 g) on tibia BMD and viscoelasticity were found. 
There are several possible explanations for the fact that this expectation was not met. It 
should be noted that although the effects of WBV on femoral bone microstructure in the 
study by Rubin et al (2002) were considerable, in general the effects of WBV on bone 
microstructure and BMD have shown to vary per site, species, and vibration parameters 
(magnitude, frequency, duration). In fact, the WBV treated rats have significantly lower 
lumbar BMD than non-treated group. Furthermore, maximum load of rat vertebrae was 
significantly reduced in WBV treated rats. The only beneficial effect from WBV 
treatment is that it significantly reduced postmenopausal osteoporotic weight gain.  This 
result indicates that the prevalent vibration therapy may not provide a curative effect in 
all conditions; on the contrary, negative results may occur in certain WBV regimen. This 
finding reveals the need to reconsider using WBV in osteoporosis prevention and 
treatment. We conclude from our results that WBV should not be recommended as a safe 
treatment to all osteoporotic patients. Since the optimal parameters were still under 
research, WBV should not be recommended for long-term usage. 
The overall results of the present study provide a better understanding of pathogenesis of 
osteoporosis, and present a novel evaluation of different osteoporotic medication efficacy 
(combination of drugs, as well as whole-body vibration) in bone viscoelasticity aspect. 
For the first time, it is observed that: 
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 Osteoporosis does not only change bone quantity and microstructure, but also 
affect nano and macro level bone viscoelasticity (η, E‟ and tan δ). 
 This deterioration in bone viscoelasticity can be partially restored by different 
treatments. 
 Additive therapeutic effect of combination treatment (PTH and ibandronate) in 
osteoporotic bone geometry, BMD and viscoelasticity.  
 A positive correlation between tan δ and ultimate strength during normal daily 
activity frequency range (0.9-6 Hz). 
 Viscoelasticity is a useful new tool to assess various treatment efficacies in 
osteoporotic rat model. 
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7.2  Future work 
In methodology, complementary Atomic Force Microscopy (AFM) and Raman 
Spectroscopy (RS) could be used to complement the current measurements. Firstly, the 
roughness of our nanoindentation samples was not quantified. Preparation protocol of 
nanoindentation sample varies from one study to another. Thus different sample 
roughness was induced in each study. According to our preliminary trials, it could range 
from 100 to 300 nm depending on polishing conditions. However, sample roughness was 
seldom reported in literature. The absence of this parameter creates the difficulty in 
comparison between studies and reproducibility of the results.  For example, if an 
indentation depth of 800 nm were reported, the real penetration into the bulk sample 
could range from 500 nm to 700 nm depending on preparation technique. With the taping 
mode of AFM, the sample roughness could be well quantified before each indentation. 
An AFM scanning on the residue after the indentation would also provide useful 
information on visualization and quantification of the micro damage occurred. 
Secondly, characterization of tissue composition around each indentation residue by RS 
can be recommended. In Chapter 4, SEM was used to study the drug induced alterations 
in collagen alignment. However, whether the matrix composition has been changed is 
still unknown. In addition, the bone matrix composition differs on hierarchical nano level 
structures. Thus, instead of traditional element analysis of bulk bone, RS quantification of 
the local tissue composition around indentation residue should be more suitable.  
OVX rat model has been widely used to investigate osteoporotic drug efficacy. Compare 
to larger animal model, it has advantages of short life-span, low cost, easy handling skill 
and less ethical issue evolved. However, there are discrepancies between rat and human 
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cortical bone, i.e., the absence of harvesian remodeling in rats (Turner et al., 2001). Thus 
the results observed in this study may not have good compliance with clinical 
observations. Animal models with well developed osteon structure, i.e., Rabbit, beagle 
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